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 The cancers of liver, colon and breast are amongst the top five most prevalent and most 
fatal worldwide. Currently, surgical resection, radiotherapy and adjuvant chemotherapy, in some 
cases combined with certain approved targeted agents, constitute the front line therapies for 
hepatocellular carcinoma (HCC) and colorectal cancer (CRC). As the Raf/MEK/ERK pathway is 
frequently deregulated in HCC, sorafenib, a Raf kinase inhibitor, became the first systemic 
therapy approved for the treatment of patients with HCC. However, sorafenib only produced 
modest effects with low response rates in the clinic. Similarly, regorafenib, a more potent and 
more soluble derivative of sorafenib, which was approved for the treatment of metastatic CRC, 
has had a poor response rate in the clinic. Since phosphodiesterase type 5 has been reported to be 
overexpressed in HCC and CRC, we hypothesized that sildenafil, a phosphodiesterase type 5 
inhibitor, could enhance the toxicities of sorafenib and regorafenib in HCC and CRC cells, 
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respectively. Our in vitro data indicated that the drugs interacted strongly to kill cancer cells via 
induction of ER stress, autophagy and apoptosis. In accordance with these findings, our in vivo 
data demonstrated a significant reduction in tumor growth. 
 The second study was conducted based on the growing body of evidence about the 
significant contribution of EGFR and JAK/STAT signaling to the breast tumorigenesis. Thus, we 
hypothesized that the concurrent inhibition of JAK/STAT and EGFR signaling pathways would 
kill breast cancer cells in a synergistic manner. Our preliminary in vitro data demonstrated that 
the inhibition of these two pathways by lapatinib, a dual ERBB1/2 inhibitor, and ruxolitinib, a 
JAK1/2 inhibitor, synergistically killed breast cancer cells of all types, including the resistant 
triple negative subtype. Our mechanistic studies showed that the combination of ruxolitinib and 
lapatinib triggered cytotoxic mitophagy, and autophagy-dependent activation of BAX and BAK 
leading to the mitochondrial dysfunction.  
 Collectively, our studies strongly argue that the combination of sorafenib/regorafenib and 
sildenafil as well as the combination of ruxolitinib and lapatinib can possess significant 
therapeutic value in the clinic. 
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CHAPTER 1: Introduction to Cancer Therapy 
 
Cancer 
 
Cancer is a complex compilation of distinct genetic abnormalities, which collectively 
alter the way normal cells, in a particular part of the body, function, grow and divide.1 Consistent 
with Darwinian principles, cancer stems from random mutations within the genes of normal cells 
in a multistep process that enable these cells to activate or modify certain cellular programs, 
including proliferation, migration and apoptosis.1,2 These mutagenic alterations occur in the form 
of activating (gain-of-function) mutations, amplification and/or overexpression of genes that 
promote proliferation (oncogenes), as well as inactivating (loss-of-function) mutations, deletion 
and/or epigenetic silencing of genes that inhibit growth (tumor suppressor genes).1,3 Many 
studies have concluded that both intrinsic naturally-occurring errors in DNA replication and 
extrinsic factors, such as exposure to carcinogens, can affect the rate of mutagenesis although it 
is not very well clear what portion of total cancer risk stems from each source.4  
Despite the variable genetic profile of cancer cells, they share common biological 
characteristics, which have been referred to as the hallmarks of cancer. According to Hanahan 
and Weinberg2, these acquired capabilities that distinguish cancer cells from the normal cells 
include activating proliferative signaling, inhibiting growth suppressors, resisting cell death, 
gaining replicative immortality, promoting angiogenesis, and activating invasion and metastasis.  
In addition to the acquisition of the hallmark traits, which are highlighted as the major 
driving force behind carcinogenesis, the cancer cells also possess the capability to recruit the 
surrounding stromal cells to form a histologically diverse microenvironment that enhances 
growth, progression and metastasis.1,2 In other words, a tumor is not simply a homogenous 
aggregate of cancer cells but rather a more complex heterogeneous population of cells, including 
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cancer cells, cancer stem cells, immune inflammatory cells, endothelial cells and cancer-
associated connective tissue.1,2 The formation of this advanced microenvironment around the 
cancer cells adds another layer of complexity to understanding the mechanisms of tumorigenesis, 
and implies that the tumor biology cannot be fully understood without studying the individual 
cells within it.2   
Currently, cancer is the second leading cause of death worldwide behind the 
cardiovascular diseases. In the United States, a quarter of all deaths are caused by cancer, and 
new statistics suggest that nearly half of men (~45%) and a third of women (~38%) in the United 
States will be affected by this fast-growing disease during their lifetimes.5,6 The cancers of lung, 
colorectum, prostate and breast continue to be among the deadliest, accounting for half of the 
cancer-related mortalities in American men and women.6 On the bright side, due to the advent of 
new therapies, a decrease in tobacco consumption, more effective screening and early detection, 
cancer death rates dropped 22.9% in men and 15.3% in women between 1990-2008.6   
A Concise History of Cancer Treatment 
 A great body of evidence suggests that cancer is not a disease of modern era as 
paleopathologic findings revealed that cancer existed in prehistoric times, long before human 
species evolved.7 The earliest case of cancer in humans was found in Edwin Smith Papyrus 
dating back to approximately 3000 BC, being described as an incurable grave disease.7 Similar 
reports of cancer cases were found in ancient Egyptian manuscripts.5 The Egyptians utilized 
cautery, knives, salts and arsenic paste as means of treatment whereas the Sumerians, Chinese, 
Indians and Persians resorted to herbal remedies.7 Later the Romans treated aggressive cancers 
by surgical resection, or amputation in more severe cases, followed by herbal remedies. This 
5 
 
 
 
approach remained to be the standard procedure in cancer treatment before the Catholic Church 
prohibited all surgical operations in 1215.5,7  
 The major breakthrough in cancer therapy came at the turn of the 20th century by an 
accidental observation of the effect of mustard gas on the depletion of bone marrow and lymph 
nodes. Supported by further studies, the use of nitrogen mustard as a treatment for lymphoma 
increased rapidly in the United States. A few years later, it was discovered that folate deficiency 
could replicate the effects of nitrogen mustard on bone marrow. These findings triggered the use 
of synthesized anti-folate drugs, most notably methotrexate, as a treatment for leukemia.8   
 In the middle of 1950s, Charles Heidelberger and his colleagues noticed a significant 
increase in uracil uptake by hepatoma cells relative to normal tissue. Their efforts resulted in the 
synthesis of 5-fluorouracil (5-FU), which was later utilized against a broad range of solid tumors. 
Their approach to target a certain biochemical pathway that cancer cells relied upon was the very 
first example of what we refer to as targeted therapy today.8,10    
 The initial optimism of curing cancer with the use of alkylating agents and 
antimetabolites soon turned into disappointment as many cases of recurrence and metastasis were 
reported in the patients. In late 1960s, cancer treatment moved towards combination 
chemotherapy, and chemotherapeutics were applied in conjugation with surgery and/or 
radiation.8,9 In adjuvant therapy, the chemotherapy is administered after surgery to eliminate the 
remaining cancer cells whereas in neoadjuvant therapy, the chemotherapy is applied before 
surgery in order to reduce the size of the tumor.5,9  
 Eventually in the late 20th century, through the advancements in genomics, many 
oncogenes and tumor suppressor genes were identified. The genome sequencing of a variety of 
cancer cells suggested that many of them possessed abnormalities within genes that coded for 
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protein kinases. Subsequently, a new class of anti-cancer therapeutics known as kinase inhibitors 
was soon developed. These small molecules are believed to hold significant promise to treat all 
sorts of malignancies as they aim at specific targets within the cancer cells and have the 
capability to exploit oncogene addiction.8,11,14 The development of imatinib (Gleevec) against the 
aberrant nonreceptor tyrosine kinase Bcr-Abl in patients diagnosed with chronic myeloid 
leukemia (CML) is a perfect example of targeted therapy as complete responses were observed 
in 60-70% of cases.8,12,14 In addition to kinase inhibitors, monoclonal antibodies such as 
trastuzumab (Herceptin) and antisense inhibitors have also been developed and studied during 
the past two decades. Currently, the efficacy of many of these targeted drugs in a variety of 
cancers is being evaluated in the clinic, both individually and in combination with other targeted 
or chemotherapy agents. 
Targeted Therapy 
 Chemotherapy has been the cornerstone of cancer therapy for decades; however, its 
response rate remains low as most cytotoxic chemotherapeutics yielded narrow therapeutic 
index, caused significant toxicity, and resulted in palliative, unpredictable responses. 
Furthermore, poor penetrability, low absorption, rapid elimination, development of drug 
resistance, and the complex heterogeneous nature of the tumor microenvironment contributed to 
their dysfunctionality.12,13,23 Therefore, a more target-specific approach based on better 
understanding of the tumor biology started to take root in the post-genomic era. Since all drugs 
have targets, the term targeted therapy might be misleading. Therefore, we need to define this 
category of therapies first before making any comparisons to the conventional chemotherapy.  
Targeted therapy refers to treatments, in which a target within the cancer cells, cancer 
stem cells, or the tumor microenvironment is first identified, before a selective inhibitory drug is 
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developed against it. The development of Herceptin against Her-2/Neu, an oncogenic receptor 
tyrosine kinase involved in progression of Her-2 positive breast cancer, is just an example 
amongst many.10 Evidently, the major benefit of this type of tailored therapy is that it only 
interferes with distinct molecular targets that the cancer cells physiologically depend on, thus, 
providing high specificity, a broader therapeutic index, and less nonspecific toxicities.12   
Antiangiogenic drugs are another class of targeted therapeutics that has been broadly 
explored in recent years. It has been well established that tumor blood supply is critical for tumor 
progression and metastasis.19,21 One of the key mediators of angiogenesis is known to be 
vascular endothelial growth factor-A (VEGF-A). Inhibition of angiogenic factors such as VEGF-
A have appeared to be an effective approach with near universality application and minimal 
incidences of acquired  resistance.14,15,19 Bevacizumab is a great representative of this class of 
drugs, which binds to VEGF with high specificity thus inhibiting angiogenesis. Recent clinical 
trials have approved the effects of Bevacizumab in combination with 5-fluorouracil in extending 
survival rate in patients with metastatic colorectal cancer.15,21 Similarly, kinase inhibitors with 
anti-VEGF receptor (VEGFR) activity such as sorafenib have produced impressive results in 
treating renal cell carcinoma.14,12,20 
Drug Resistance in Cancer 
 Although the cancer genome profile is genuinely a useful tool that identifies most 
oncoprotein/tumor suppressor-related mutations, producing Gleevec-like success in most solid 
tumors through targeted therapy has been proven to be extremely challenging. In fact, over 90% 
of the targeted compounds in clinical trials fail to gain approval due to their poor efficacy.10,14 
Two major reasons have been proposed to have caused this subpar results.  
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Firstly, it is extremely difficult to distinguish the mutations that occur early in the life of a 
tumor from the ones that occur in the later stages. This can severely affect the dependency of a 
tumor on a certain mutation and the degree by which an inhibitory agent can block tumor 
growth. For instance, in case of CML, the abnormality in Bcr-Abl tyrosine kinase is generally 
agreed to be the initiating mutation, to which the significant success of Gleevec is attributed.14,18 
In contrast, there is evidence suggesting that the activating mutation in FMS-like tyrosine kinase 
3 receptor (FLT3) in patients with acute myeloid leukemia (AML) occurs later in tumor 
progression. Therefore, the phase I studies of FLT3 targeted inhibitors have not replicated the 
impressive response rate of Gleevec.14,16,17,18  
Secondly, the emergence of different forms of acquired resistance in cancer cells against 
the cytotoxic chemotherapeutics and the targeted drugs have been largely to blame for their 
dismal response rate. Here we briefly discuss some of the major mechanisms of resistance 
acquired in response to both targeted and chemotherapy. 
1. Increased expression of drug efflux pumps: among all transporter proteins, the ATP-
binding cassette (ABC) transporter family of transmembrane proteins has been most notably 
linked to multi drug resistance (MDR). This protein family consists of 49 members, grouped into 
seven subfamilies (designated A to G) that are involved in transportation of a broad range of 
substrates, including amino acids, ions, lipids, sugars and drugs across the membrane.23-26 Multi-
drug resistance protein 1 (MDR1, also known as ABCB1), MDR-associated protein 1 (MRP1, 
also known as ABCC1) and breast cancer resistance protein (BCRP, also referred to as ABCG2) 
are the 3 members of this family that are overexpressed in many cancers. These transporters can 
efflux a wide range of chemotherapeutics such as taxanes, topoisomerase inhibitors and 
antimetabolites.23,24,26 Statistical studies have established a correlation between increased 
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expression of ABC transporters and a poor response to chemotherapy.27 For instance, the low 
response rate to anthracyclines in pancreatic cancer has been suggested to be in part due to the 
MDR phenotype.28,29 In spite of the initial optimism, the combination of the inhibitors of these 
transporters with the standard of care chemotherapy generated disappointing results. For 
instance, the combination of valspodar, a specific ABCB1 inhibitor, in combination with 
paclitaxel and carboplatin in patients with stage IV ovarian or primary peritoneal cancer did not 
yield any benefit as compared to chemotherapy alone.24,30 These findings argued that the 
contribution of MDR phenotype to drug resistance might not be as significant as previously 
presumed.23,24 
2. Drug inactivation: another obstacle in cancer therapy is diverse cellular mechanisms 
of drug inactivation or insufficient drug activation. Resistance to the platinum drugs such as 
cisplatin by glutathione is a good example of such inactivation mechanisms.31 Epigenetic 
silencing can also contribute to the activity of certain drugs.23 For instance, o6-methylguanine-
DNA methyltransferase (MGMT) is a repair enzyme whose function counteracts the formation 
of DNA double strand breaks induced by temozolomide (TMZ) in patients suffering from 
glioblastoma multiforme (GBM). The clinical studies have indicated that the methylated status of 
MGMT promoter in GBM patients who received concurrent radiotherapy and TMZ treatment 
was associated with a significant increase in survival time as this group of patients lived on 
average 6.4 months longer than the patients who possessed normal MGMT expression level.32,33 
3. Secondary mutations in drug targets: drug resistance can also stem from the 
secondary somatic alterations within the oncogenic targets. The first case of this resistance 
mechanism was identified in CML patients treated with Gleevec, and similar genetic alterations 
have been observed in other cancers ever since.22,23 In general, these mutations either promote an 
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active enzymatic conformation or the target or prevent drug binding.22 One of The best examples 
of such target alterations is the gatekeeper mutations within the catalytic domain of epidermal 
growth factor receptor (EGFR) in patients with non-small cell lung cancer (NSCLC), which 
increases the affinity of EGFR for ATP, thus lowering the efficacy of EGFR inhibitors. These 
alterations have been directly linked to the dramatic response rates of erlotinib and gefitinib in 
patients with NSCLC.22,23,34  
4. DNA damage repair: Most chemotherapeutics cause DNA damage either directly as 
seen by platinum drugs or indirectly as observed by the function of topoisomerase inhibitors. 
Therefore, the capacity of DNA damage repair in cancer cells, as explained by the 
aforementioned example of MGMT in TMZ therapy, plays a critical role in the response rate of 
chemotherapy.23,33 Thus, targeting the components of the DNA repair machinery has emerged as 
a new strategy to enhance the toxicity of chemotherapeutics. The development of poly (ADP-
ribose) polymerase 1 (PARP1) inhibitors exemplifies this targeted approach. PARP1 is a 
ubiquitous single-strand-break DNA repair enzyme, and its inhibition results in accumulation of 
single-strand breaks followed by double-strand breaks.23,35 A phase I trial of olaparib, a potent 
PARP1 inhibitor, in patients with breast and ovarian cancer, including carriers of mutated 
BRCA1 and BRCA2 genes, generated positive results.36 There are also ongoing clinical trials 
evaluating the effect of olaparib in combination with chemotherapy in all solid tumors.35    
5. Deregulation of apoptotic components: as previously mentioned, resistance to cell 
death is one of the hallmarks of cancer, thus it is evident that deregulation of apoptosis is one of 
the mechanisms of drug resistance utilized by cancer cells. This deregulation can occur in both 
pro-apoptotic and anti-apoptotic components of the programmed cell death. Previous studies 
have reported that overexpression of anti-apoptotic proteins caused resistance to 
11 
 
 
 
chemotherapeutics in leukemic cells.23,37 Studies from our laboratory also suggested that 
lapatinib-resistant HCT116 cells had higher expression of anti-apoptotic proteins Bcl-xL and 
Mcl-1 and reduced expression of pro-apoptotic protein BAX compared to the wild type cells, and 
that inhibition of Mcl-1 restores lapatinib toxicity to a great extent.38 
6. Activation of pro-survival signaling pathways: the activation of survival pathways 
in response to chemotherapy is another way for cancer cells to resist cell death. Plenty of studies 
have proposed the activation of EGFR as a resistance mechanism to chemotherapy.23 Similar 
studies indicated that EGFR inhibitors could enhance the effects of paclitaxel and 5-FU in renal 
and colorectal cancer, respectively.39,40 Furthermore, some clinical trials have supported the 
beneficial addition of EGFR inhibitors to irinotecan-based therapy, leading to approval of these 
targeted agents by the Food and Drug Administration (FDA) for treatment of certain subtypes of 
colorectal cancer.23,41  
7. Activation of bypass mechanisms: activation of compensatory parallel signaling 
pathways has emerged as a major concern rendering cells resistant to targeted therapy. In this 
mechanism of resistance, also referred to as oncogenic bypass, activation of an alternative kinase 
through an adaptive feedback loop or a secondary mutation triggers signaling through parallel 
pro-survival pathways, which ultimately counteracts the effect of the targeted agent.22,23 A good 
example of this type of resistance is the activation of ERBB3 and its downstream PI3K/AKT 
pathway in response to EGFR inhibitors such as cetuximab.42,43 Similar mechanism has been 
reported in patients with NSCLC that responded poorly to gefitinib, as an amplification of MET 
proto-oncogene led to the activation of ERBB3 compensatory signaling.44  
Advantages of Combinatorial Targeted Therapy 
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 Investigating the various mechanisms of drug resistance undoubtedly provides a plethora 
of information that can be directed towards the development of more effective future therapies. 
For example, the increased affinity of the mutant EGFRT790M for ATP in patients with NSCLC 
has led to the production of new restructured irreversible inhibitors that bind to EGFR catalytic 
cleft more readily than erlotinib and gefitinib. This new generation of EGFR inhibitors have 
shown improved efficacy in murine models.22,45 However, most types of acquired resistance are 
mediated by the activation of the alternative compensatory pathways rather than alteration of the 
drug target itself. Therefore, resorting to a rational combinatorial approach seems imperative. 
There are two distinct types of drug combinations: 
 1. Combinations of targeted drugs with chemotherapy: many studies have recently 
indicated that the specific targeted agents can enhance the effect of chemotherapy in a variety of 
tumor types through interference with the DNA repair enzymes or inhibition of pro-survival 
pathways. The FDA-approved combination of lapatinib with capecitabine in women with 
advanced breast cancer resistant to trastuzumab, or the combination of cetuximab with irinotecan 
in patients with metastatic colorectal carcinoma are two examples of how the targeted inhibition 
of an activated survival pathway leads to a more responsive chemotherapy.11,41,46 Concurrent 
inhibition of DNA repair enzymes (e.g. PARP1) or checkpoint kinases (e.g. CHK1) with 
chemotherapy has also significantly improved the standard of care in a variety of cancers.35,47   
 2. Combinations of target-specific drugs: a major setback to single-agent targeted 
therapy is the potential for crosstalk between pro-survival pathways. This may result in the cell 
activating an alternative survival pathway in the event of blockade of a specific pathway; thus, 
leading to drug resistance. Therefore, there is growing evidence that the use of targeted 
therapeutics in combination provides a more rational strategy to increase the efficacy of 
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treatment. The combinatorial targets might lie within the same oncogenic pathway (referred to as 
vertical) or located within two distinct pathways (described as horizontal).11 For instance, recent 
clinical trials revealed that EGFR inhibitors, used as single agents, are of little therapeutic benefit 
in patients with GBM, which commonly possess deregulated EGFR signaling pathway.48 One of 
the mechanisms of resistance to EGFR inhibition in GBM cells has been shown to be the 
upregulation of platelet-derived growth factor receptor β (PDGFRβ).49 A recent study from our 
laboratory indicated that the addition of sorafenib, a multi-kinase inhibitor with anti-PDGFRβ 
activity, significantly enhances lapatinib toxicity in GBM cells.50 Another relevant example is 
the crosstalk between estrogen receptors (ER) and EGFR family members, which has been 
shown to modulate resistant to hormone therapy.51,52 These findings led to accelerated approval 
of lapatinib in combination with letrozole, an aromatase inhibitor, for the treatment of 
postmenopausal women with ER-positive metastatic breast cancer.53 
 The purpose of this study is to introduce novel targeted drug combinations in multiple 
types of cancer using the same rationale. But prior to presenting the results, we need to introduce 
some of the important signaling pathways involved in survival and cell death, which are affected 
by the proposed drug combinations in this manuscript. 
Mitogen-Activated Protein Kinase Pathway (MAPK) 
 MAPK pathways are evolutionary conserved signaling cascades involved in fundamental 
intracellular processes such as growth, proliferation, migration and apoptosis. MAPK pathways 
consist of a three-tier kinase module in which a downstream MAPK is activated upon 
phosphorylation by MAPK kinase (MAPKK), which in turn is activated when phosphorylated by 
its upstream MAPK kinase kinase (MAPKKK). There are four major well characterized 
mammalian MAPK kinase pathways that activate four distinct terminal serine/threonine kinases, 
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ERK1/2, c-Jun amino-terminal kinase (JNK), p38 kinase and ERK5 (Figure 1).54-56 ERK1/2 is 
normally activated by growth factors whereas JNK, p38 and ERK 5 usually become activated in 
response to cytokines or environmental stress such as osmotic shock and ionizing radiation. 
Recently, two more mammalian MAPK pathways have been discovered that lead to activation of 
ERK3/4 and ERK 7/8 while the rest of the components of these pathways are currently 
unknown.54-56 Among all, the ERK1/2 MAPK signaling pathway, commonly deregulated in 
many cancers, has drawn a great deal of attention due to its pivotal role in vital cell functions 
including growth, differentiation, survival, migration and angiogenesis, and has grown as a major 
target for cancer drug discovery.54-57 Deregulation of this pathway occurs at several different 
levels as the mutational activation of Raf, Ras and their upstream receptors such as EGFR has 
been reported in a variety of human cancers.54,55 
 p38 is strongly responsive to pro-inflammatory cytokines and environmental stress, and 
gets activated by two main MAPKKs, MKK3 and MKK6. Two main substrates of p38 are MAP 
kinase-activated protein kinase 2 (MK2) and MK3. Activated MK2 and MK3 interact with 
various targets, including heat shock protein (HSP) 27, CREB, and ATF.58,59 
 The JNK kinase family (also known as stress-activated protein kinases (SAPK)) includes 
three proteins JNK1, JNK2 and JNK3, which get activated by MKK4 and MKK7 in response to 
cytokines, growth factors and stress. Upon activation, JNKs interact with numerous substrates, 
most prominently the transcription factor activator protein-1 (AP-1), which is formed by 
dimerization of the Fos and Jun proteins.60,61  
 JNKs and p38 MAPKs regulate many pathways involved in inflammation, proliferation, 
differentiation, survival and cell death. They can act both as tumor suppressors and oncoproteins 
depending on cell type, duration of activation and the nature of stimulus.60,62   
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Figure 1. Four major mammalian MAPK pathways. MAPK pathways are comprised of three-
tier kinase module in which a MAPKKK phosphorylates the downstream MAPKK, which in turn 
phosphorylates its downstream serine/threonine MAPK. Among the MAPKs activated by these 
four pathways, only ERK1/2 responds to growth factors. ERK5, JNK and p38 are mainly 
activated due to environmental stress such as osmotic shock and ionizing radiation. 
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Ras/Raf/MAPK Pathway 
 When growth factors bind to their receptors, they induce dimerization and auto-
phosphorylation of tyrosine residues on the catalytic domains of these receptors. These phospho-
tyrosines act as docking sites for growth factor receptor-bound protein 2 (GRB2), an adaptor 
protein, and sons of sevenless (SOS), an exchange factor, which together result in the activation 
of Ras (Figure 2).55,57,63  
Ras GTPases (H-, K- and N-Ras) act as molecular switches that mediate activation of 
many signaling pathways. Inactive guanosine diphosphate (GDP)-bound Ras activity is regulated 
by guanine nucleotide exchange factors (GEFs), such as SOS, which promote the formation of 
active guanosine triphosphate (GTP)-bound Ras, whereas GTPase-activating proteins (GAPs), 
such as neurofibromin 1 (NF1), induce GTP hydrolysis and formation of inactive GDP-bound 
Ras. Activated GTP-bound Ras then recruits Raf from the cytosol to the cell membrane where a 
multi step activation process occurs.54,55,57 Ras regulates survival and proliferation pathways, and 
is constitutively activated in approximately 30% of all cancers with pancreas (90%), colon (50%) 
and lung (30%) having the highest rates of aberrant Ras signaling.55 The most common 
mutations of Ras are related to GAP insensitivity, which maintains Ras in an active GTP-bound 
state. As GAP-based targeted therapies failed to impress, the downstream effectors of Ras have 
grown as more suitable therapeutic targets.55,57 
 Raf serine/threonine kinases are direct downstream effectors of Ras. There are  three 
different forms of Raf (A-, B- and C- Raf) whose structures are similar, but differ considerably in 
their modes of regulation, tissue distribution, and the ability to activate MAPK/ERK kinase 
(MEK).54,63 B-Raf gets activated directly by Ras whereas A- and C-Raf require additional serine-
and tyrosine phosphorylation to become fully active.64 All three isoforms are able to 
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phosphorylate MEK with B-raf being the strongest activator and A-Raf the weakest.63 B-Raf 
mutations are quite prevalent in malignant melanomas (~66%) and many other cancers such as 
colon and thyroid.54 The most common B-Raf active mutant form is B-RafV599E, which 
constitutively induces ERK signaling.64  
Activated Raf then phosphorylates MEK1/2 at two serine residues located on the kinase 
domain, which in turn binds to and phosphorylates ERK1/2. Activated ERK1/2 can translocate to 
the nucleus and induce genetic responses that regulate processes such as proliferation, 
differentiation, survival, migration and angiogenesis.54-57 ERK1/2 can also modulate cell survival 
through interaction with cytosolic substrates, most notably p90 ribosomal S6 kinase (p90RSK). 
Activated p90RSK phosphorylates pro-apoptotic protein BAD resulting in its inactivation. It also 
activates cAMP response element-binding protein (CREB), which translocates to the nucleus and 
induces transcription of anti-apoptotic genes.65 Moreover, ERK1/2 can directly mediate 
phosphorylation and proteasome-dependent degradation of pro-apoptotic protein BIM.66 
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Figure 2. Ras/Raf/MAPK signaling pathway. Upon ligand binding, the tyrosine residues on 
the kinase domain of EGFRs become transphosphorylated, which act as docking sites for the 
adaptor protein GRB2. SOS binds to GRB2 and activates Ras by exchanging GDP for GTP. 
GTP-bound Ras recruits Raf from cytosol to the membrane and activates it, which in turn 
activates MEK1/2 by phosphorylating two distinct serine residues. Activated MEK1/2 
subsequently activates ERK1/2, which translocates to the nucleus and induces multiple cellular 
responses. ERK1/2 also interacts with cytosolic targets such as p90RSK and BIM leading to 
activation of survival pathways.  
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PI3K/AKT Pathway 
When growth factors bind to the membrane receptor tyrosine kinases including EGFR, 
PDGFR, or insulin-like growth factor 1 receptor (IGF1R), they induce receptor phosphorylation 
and membrane recruitment of PI3K. PI3K is a lipid kinase that is comprised of two separate 
subunits, a regulatory p85 and a catalytic p110, which heterodimerize upon activation. Activated 
PI3K phosphorylates the lipid phosphatidylinositol 4,5-biphosphate (PIP2) generating the second 
messenger phosphatidylinositol 3,4,5-triphosphate (PIP3). PIP3 in turn recruits both 
phosphatidylinositol-dependent protein kinase 1 (PDK1) and AKT to the membrane, where AKT 
becomes phosphorylated on threonine 308 (T308) by PDK1 and additionally on serine 473 
(S473) by the mechanistic target of rapamycin complex 2 (mTORC2) to become fully active 
(Figure 3). Activated AKT induces survival, proliferation and growth through phosphorylation of 
multiple downstream effectors. The PI3K/AKT pathway is negatively regulated by phosphatase 
and tensin homolog (PTEN), a lipid phosphatase that dephosphorylates PIP3 to PIP2. 67-69   
AKT promotes survival through interaction with multiple substrates. It directly blocks 
activation of pro-apoptotic proteins BAD and pro-caspase 9. It also phosphorylates mouse 
double minute chromosome 2 (MDM2). Phosphorylated MDM2 translocates to the nucleus 
where it induces degradation of p53, an important tumor suppressor, through its E3 ubiquitin 
ligase activity. In addition, AKT inhibits transcription factor forkhead box 1 (FOXO1), thus 
blocking FOXO-mediated transcription of apoptotic factors.67-69  
AKT also induces proliferation through inhibition of glycogen synthase kinase-3β (GSK-
3β) resulting in the accumulation of cyclin D1 and progression of cell cycle.67-69  
Furthermore, AKT promotes protein synthesis and cell growth through activation of 
mTOR complex 1 (mTORC1). In this process, AKT inhibits tuberous sclerosis complex 2 
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(TSC2), which with its binding partner TSC1 act as a GAP for the Ras homolog enriched in 
brain (Rheb) GTPase. Rheb strongly activates mTORC1 when it is in an active GTP-bound state. 
Activated mTORC1 phosphorylates p70 S6 kinase (p70S6K) and eukaryotic initiation factor 4E 
(eIF4E)-inhibitory binding protein (4EBP). Activation of p70S6K and eIF4E enhances mRNA 
translation and increases protein synthesis.67-69 mTORC1 is also a major regulator of autophagy. 
Under nutrient starvation, AMP activated protein kinase (AMPK) phosphorylates Unc-51 like 
autophagy activating kinase 1 (ULK1) on serine residues 317 and 777, leading to initiation of 
autophagy. Under nutrient sufficiency, mTORC1 phosphorylates ULK1 on serine 757, thus 
disrupting the interaction between ULK1 and AMPK.70  
Increasing evidence suggest that many cancers rely on activation of AKT and mTORC1 
to drive tumorigenesis, and commonly deregulated status of this pathway has turned it into an 
attractive target for therapeutic intervention. Activating mutations and gene amplification occur 
at different levels in this pathway. For instance, loss-of-function mutations and complete loss of 
PTEN is frequently observed in many cancers, including GBM, colon, breast, lung and 
prostate.71 Gene amplification of p110 and AKT as well as activating mutations of p85 occur in 
many cancers, including ovarian, breast and colon.72 
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Figure 3. PI3K/AKT signaling pathway. The lipid kinase PI3K binds the kinase domain of the 
EGFR receptor, and phosphorylates PIP2 to generate PIP3. PIP3 recruits both PDK1 and AKT to 
the membrane where PDK1 phosphorylates AKT. Activated AKT induces protein synthesis and 
survival through interaction with various substrates. mTOR, a major AKT target that acts as a 
nutrient sensor,  phosphorylates p70S6K and 4EBP. Released eIF4E and phospho-p70S6K 
translocate to the nucleus and induce protein synthesis. This pathway is negatively regulated by 
phosphatase PTEN, which dephosphorylates PIP3 to PIP2. 
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JAK/STAT Signaling Pathway 
 The Janus family of kinases (JAKs) includes JAK1, JAK2, JAK3 and tyrosine kinase 2 
(TYK2), which are involved in transduction of signals received from a variety of physiological 
stimuli, including cytokines and growth factors. JAK1 is required in the signaling of pro-
inflammatory cytokines such as interleukin (IL)-6, IL-1, and interferon-Ɣ (IFN-Ɣ). JAK2 is 
important for hematopoietic growth factors, growth hormone and prolactin signaling. JAK3 plays 
a role in mediating immune function whereas Tyk2 functions in part with JAK 2 and JAK3 to 
transduce cytokine signaling. The function of JAK kinases are essential in cytokine signaling 
since the members of the cytokine receptor superfamily lack intrinsic kinase activity.73,74   
 The signal transducers and activators of transcription (STAT) proteins are a family of 
transcription factors that function downstream of JAKs. Seven members of the STAT family 
have been identified so far (STAT1-4, STAT 5a, STAT 5b, and STAT6), which contain a SRC 
homology 2 (SH2) domain, a DNA binding domain, and a transactivation domain.75-77 
 Upon cytokine binding and receptor dimerization, JAKs are recruited to the cytoplasmic 
domains of the receptors where they phosphorylate specific tyrosine residues. Subsequently, 
STATs bind these phosphorylated residues through their SH2 domains, and get tyrosine 
phosphorylated on their transactivation domains by the JAKs. Once activated, STATs homo- or 
heterodimerize through reciprocal phosphotyrosine-SH2 domain interactions. The dimmers then 
translocate to the nucleus where they interact with other transcription modulators to induce gene 
expression.73-76 Among the genes regulated by STATs are those coding for pro-survival proteins, 
such as Bcl-2 family of proteins (e.g. Bcl-xL), those promoting cell proliferation, such as cyclin 
D1, and those involved in angiogenesis and metastasis, such as VEGF (Figure 4).78   
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 JAK/STAT pathway is negatively regulated by two different families of proteins; the 
suppressors of cytokine signaling (SOCS) proteins, and the protein inhibitors of activated STAT 
(PIAS). SOCS proteins bind the phosphorylated residues on the cytokine receptors through their 
SH2 domains. SOCS-1 has become known as a major tumor suppressor that directly binds JAK2 
and inhibits JAK/STST signaling.77,79 The aberrant methylation of SOCS-1 gene has been 
observed to a great extent in hepatocellular carcinoma, which shows the significance of 
JAK/STAT signaling in tumor progression.80 The PIAS family includes PIAS1, PIAS3, PIASx 
and PIASy. These proteins bind activated STAT dimmers and inhibit their function through 
multiple different mechanisms.77,79 
 Constitutively activated STATs have been numerously reported in a variety of cancers 
mainly due to deregulation of their upstream signaling proteins. STATs act as a point of 
convergence for numerous upstream tyrosine kinases, and hold significant promise for the 
development of new anti-cancer therapeutics. Many studies have indicated the role of STAT3 
and STAT5 in oncogenesis, and their inhibition has been shown to be associated with tumor 
suppression and cell death. In addition, activated STAT3 and STAT5 signaling has been 
observed in breast, lung, and head and neck cancer mediated by increased cytokine signaling.75,77 
 Activation of STATs can also be caused by aberrant JAK signaling. A somatic gain-of-
function mutation (V617F) in JAK2 is present in 50-60% of patients with primary myelofibrosis 
and essential thrombocythemia. Amplification of JAK2 has also been implicated in 30-50% of 
patients with Hodgkin lymphoma and primary B-cell lymphoma. Recently, targeted inhibition of 
JAK2 generated promising results in patients with myelofibrosis leading to the approval of 
ruxolitinib (Jakafi) by FDA in 2011.73,74  
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Figure 4. JAK/STAT pathway. Upon cytokine binding and receptor dimerization, JAKs are 
recruited to the receptor site where they phosphorylate tyrosine residues on the cytosolic domain 
of the receptor. The phosphotyrosines act as docking sites for STATs to bind, and subsequently 
get activated through phosphorylation by JAKs. Dimerized STATs translocate to the nucleus and 
induce expression of genes involved in proliferation, differentiation and survival. This pathway 
is negatively regulated by SOCS and PIAS family of proteins. 
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Epidermal Growth Factor Receptor Tyrosine Kinase 
 The EGFR/ErbB family is a critical component in the autocrine growth regulation of 
carcinoma, and is comprised of four different receptors; EGFR/ErbB1, ErbB2/HER2, 
ErbB3/HER3, and ErbB4/HER4. All of these trans-membrane proteins are within the 170-190 
kilo Dalton (kDa) size range and are composed of three different domains; the glycosylated 
extracellular ligand-binding domain, a single hydrophobic trans-membrane domain, and an 
intracellular catalytic domain.81,82 The hydrophobic domain anchors the receptor in the 
membrane and connects the cysteine-rich growth factor binding extracellular domain to the 
intracellular tyrosine kinase catalytic domain. Unlike ErbB1, 2 and 4 which are catalytically 
active, ErbB3 does not have an active tyrosine kinase domain, but remains competent for ligand 
binding and signal transduction. There is no known ligand that binds ErbB2, but ErbB2 remains 
a favorite dimerization partner for the rest of the members.81,84 
 Ligand binding or receptor over-expression induces homo- or hetero-dimerization of 
ErbB receptors, which results in trans-phosphorylation of tyrosine residues located on the 
intracellular catalytic domain. The phospho-tyrosine residues on the cytoplasmic side of the 
receptor act as docking sites for SH2 domain-containing signaling proteins that are involved in 
activation of multiple downstream metabolic signaling cascades including PI3K/AKT, 
Ras/Raf/MAPK and phospholipase C (PLC)/ protein kinase C (PKC).81,82 EGFR signaling also 
activates STATs, which lately has been demonstrated to be mediated by Src family of kinases 
(Figure 5).83  
 Aberrant ErbB signaling has been observed in a variety of cancers, and its activation has 
been linked to invasion, metastasis, chemoresistance, and poor clinical outcome. Overexpression 
of EGFR has been reported in many cancers, including 40-80% of NSCLC, 72-82% of colorectal 
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cancer (CRC), and 50-90% of renal cell carcinoma. Amplification of HER-2 is present in 25-
30% of breast cancers. EGFR is also amplified in approximately 40-50% and over-expressed in 
more than 60% of glioblastomas. Nearly 40% of the GBMs with EGFR amplification possess a 
constitutively active mutant form of the receptor, EGFRvIII. Therefore, EGFR tyrosine kinases 
have turned into one of the most sought after targets in cancer therapy.85,86 
 Two classes of EGFR inhibitors have been developed; monoclonal antibodies and 
tyrosine kinase inhibitors (TKI). Monoclonal antibodies, such as trastuzumab and cetuximab, 
bind to the extracellular domain of the receptor, and prevent ligand binding whereas TKIs, such 
as erlotinib and lapatinib, block the ATP binding pocket of the receptors, thus blocking receptor 
activation.82,85 In spite of the initial positive results, a variety of mechanisms of acquired 
resistance have been observed in response to targeted EGFR therapeutics, which have drastically 
lowered their success rates. The occurrence of secondary mutations, activation of parallel 
tyrosine kinase signaling pathways, and loss of tumor suppressors, such as PTEN are just a few 
examples of drug resistance mechanisms frequently counteracting EGFR inhibition-based 
therapies. Therefore, there is growing evidence that the combination of EGFR inhibitors with 
chemotherapy or other signal-transduction inhibitors will create a more potent therapy.82  
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Figure 5. EGFR signaling. Ligand binding induces trans-phosphorylation of tyrosine residues 
located on the intracellular catalytic domain. The phospho-tyrosine residues on the cytoplasmic 
side of the receptor act as docking sites for SH2 domain-containing signaling proteins that are 
involved in activation of multiple downstream metabolic signaling cascades, including 
PI3K/AKT, Ras/Raf/MAPK and PLC/PKC. STATs also get activated in a Src-mediated fashion. 
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Nitric Oxide Signaling 
 Nitric oxide (NO) is a small uncharged highly diffusible gaseous molecule that plays a 
critical role in regulation of cardiovascular and immune system. NO is generated through the 
catalytic activity of NO synthases (NOS), which convert L-arginine and molecular oxygen to L-
citrulline and NO.87,88 NOS activity depends on several cofactors, including NADPH and 
tetrahydrobiopterin (BH4). BH4 plays a critical role in NOS activity. Small ratio of BH4 relative 
to its oxidized form, dihydrobiopterin (BH2), causes NOS uncoupling, leading to production of 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) rather than NO. Uncoupling 
of NOS results in a decrease in vascular NO level, which commonly occurs during aging, 
inflammatory diseases, cardiovascular diseases and cancer.87,89 There are three isoforms of NOS: 
the inducible NOS (iNOS) that functions in inflammatory response, the endothelial NOS (eNOS) 
that generates NO as a paracrine signal in the vascular system, and the neuronal NOS (nNOS) 
that produces NO that acts as a neurotransmitter in the nervous system.87,88 
 Shear stress generated by streaming blood is sensed by the endothelial cells through 
activation of PI3K/AKT pathway. AKT phosphorylates eNOS, leading to its catalytic activation 
and generation of NO.90 Soluble guanylate cyclase (sGC) is the primary target of NO, which 
converts GTP to cyclic GMP (cGMP) upon activation. cGMP-dependent protein kinase G (PKG) 
is a major recipient of cGMP , which phosphorylates numerous targets, resulting in diverse 
physiological responses including vasodilatation and angiogenesis.87,88 Phosphodiesterases 
(PDE) are a family of enzymes that hydrolyze cAMP and cGMP to their inactive forms 5’-AMP 
and 5’-GMP, respectively (Figure 6). PDE5 inhibitors, such as sildenafil (Viagra), increase NO 
signaling by preventing the cGMP breakdown, and are currently approved for the treatment of 
erectile dysfunction and pulmonary arterial hypertension.87,88   
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Figure 6. NO signaling in the vascular system. The endothelial cells sense the shear stress 
from the streaming blood, leading to the activation of PI3K/AKT pathway. Activated AKT 
phosphorylates eNOS and induces NO generation into the adjacent connective tissue. The 
Soluble GC in the smooth muscle cells is the major target of NO. Activated sGC converts GTP 
to cGMP, which acts as an important secondary messenger. PKG is a major recipient of cGMP 
that phosphorylates numerous targets, resulting in diverse physiological responses including 
vasodilatation. This cycle is negatively regulated by PDEs that break down the cGMP to its 
inactive 5’-GMP form.  
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Apoptosis: Intrinsic and Extrinsic Pathways 
 Apoptosis, also referred to as programmed cell death type I (PCDI), is an energy-
dependent multi-step biochemical process that plays a crucial role in tissue homeostasis in 
multicellular organisms, and its deregulation contributes to many diseases, including cancer, 
autoimmunity and AIDS.  Morphologically, apoptosis is characterized by membrane blebbing, 
cell shrinkage, nucleus fragmentation, chromatin condensation and DNA degradation.91-93 There 
are two distinct apoptotic pathways: the extrinsic or death receptor pathway and the intrinsic or 
mitochondrial pathway. However, new evidence suggested that these two pathways are 
connected and the components of one pathway can influence the other.91 Both extrinsic and 
intrinsic pathways converge on the activation of specific intracellular poteases, the caspase 
family. Caspases are intracellular cysteine proteases that cleave proteins next to aspartate 
residues. Caspases, typically categorized into initiators and executioners, are synthesized as 
inactive zymogens and become activated upon cleavage by their upstream modulators.91,94 
Caspase 3 is the most  important of the executioner caspases, and is activated by any of the 
initiator caspase 8, 9 and 10 in both extrinsic and intrinsic pathways. Executioner caspases 
(caspase 3, 6 and 7) cleave various substrates including cytoskeletal and nuclear proteins, and 
also activate other proteases and endonucleases involved in protein degradation and DNA 
fragmentation.91,94 
Unlike the extrinsic pathway that is mediated by death receptors, the intrinsic pathway is 
strictly controlled by the B-cell lymphoma-2 (Bcl-2) family of proteins.91,94 The Bcl-2 family 
consists of three different classes: the anti-apoptotic group I, the pro-apoptotic group II and 
group III proteins that bind and regulate the activity of anti-apoptotic group II proteins. Group I 
family members such as Bcl-2, Bcl-x long (Bcl-xL) and myeloid cell leukaemia-1 (Mcl-1) 
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directly bind and inhibit pro-apoptotic group II family members including Bcl-2-associated X 
protein (BAX) and Bcl-2 homologous antagonist/killer (BAK). Whereas, the group III family 
members, commonly referred to as Bcl-2 homology (BH) 3-only proteins, including p53 
unregulated modulator of apoptosis (PUMA), NADPH oxidase activator (NOXA), BH3 
interacting domain death agonist (BID) and Bcl-2 interacting mediator of cell death (BIM) either 
directly or indirectly interact with pro-apoptotic group II family members and induce their 
insertion in the mitochondrial membrane.91,94 The indirect activation of BAX and BAK by BH3-
only proteins seems to be more validated since recent studies concluded that BAK can only 
induce cell death if it is displaced from prosurvival proteins Mcl-1 and Bcl-xL through BAD and 
NOXA.95 Further studies demonstrated a role for the tumor suppressor p53 in synthesis of 
PUMA and NOXA, linking DNA damage to apoptotic cell death.96,97   
The intrinsic pathway is activated by various stimuli such as viral infection, DNA 
damage and absence of certain growth factors, hormones and cytokines. After exposure to these 
stimuli, BAX and BAK homo-oligomerizae in the outer membrane of mitochondria leading to 
mitochondrial membrane permeabilization, formation of pores, and release of cytochrome-c and 
other pro-apoptotic proteins, such as caspase-activated deoxyribonuclease (CAD), apoptosis-
inducing factor (AIF) and endonuclease G, from the inter-membrane space into the cytosol.91,94 
In the cytosol, cytochrome-c binds apoptotic protease-activating factor-1 (Apaf-1), which in turn 
binds pro-caspase 9 to form a complex known as the apoptosome. Binding to Apaf-1 induces 
conformational change and activation of caspase 9, which proteolytically activates executioner 
caspase 3.91,94 Besides its proteolytic activity in the cytosol, cleaved caspase 3 can also activate 
caspase 6, another executioner caspase, and CAD by cleaving its inhibitor (ICAD). CAD 
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alongside AIF and endonuclease G, which unlike CAD function in a caspase-independent 
manner, translocate to the nucleus where they lead to DNA fragmentation.91,93,94 
The extrinsic signaling pathway is activated when death receptors bind their natural 
ligands from the tumor necrosis factor (TNF) family. These death receptors, which belong to the 
TNF receptor family, consist of a cysteine-rich extracellular domain for ligand binding and a 
cytoplasmic domain of 80 amino acids called the death domain (DD) involved in signal 
transduction.91-93 The best-characterized member of this family is Fas receptor, also known as 
cluster of differentiation 95 (CD95). The Fas receptor is a 45-kDa trans-membrane protein that 
binds to its ligand (FasL) through its cysteine-rich extracellular domain. Ligand binding induces 
conformational changes in the receptor structure that allows Fas to recruit an adaptor protein 
called Fas-associated death domain (FADD). FADD contains another important motif, the death-
effector domain (DED) that binds initiator caspases 8 and 10 through complementary DED 
domains. This death-inducing signaling complex (DISC) leads to auto-proteolytic cleavage and 
activation of caspases 8 and 10, which subsequently activate executioner caspases 3 and 7 to 
induce apoptotic response (Figure 7).91-93 The extrinsic pathway may also result in the release of 
cytochrome-c and the induction of the intrinsic pathway through activation of BID that serves as 
a substrate for caspase 8. Upon activation at the DISC, truncated BID (tBID) translocates to the 
mitochondria and induces the release of apoptotic proteins from the intermembrane space into 
the cytosol.91,98 The extrinsic apoptotic pathway is regulated at early stage by FLICE-inhibitory 
proteins (FLIP), which bind to the DISC and inhibit activation of caspase 8.92,93 
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Figure 7. Intrinsic and extrinsic apoptotic pathways. The intrinsic pathway is controlled by 
Bcl-2 family of proteins that induce release of cytochrome c from the intermembrane space of 
mitochondria into the cytosol. Cytochrome c causes Apaf-1 to bind and activate initiator caspase 
9. Cleaved caspase 9 then activates executioner caspase 3. On the other hand, the extrinsic 
pathway is initiated by binding of TNFs to the TNFRs. The TNFRs then recruit adaptor protein 
that can bind and activate initiator caspases 8 and 10. These initiator caspases in turn activate 
caspases 3 and 7. Caspase 8 can also activate BID, which can translocate to the mitochondria and 
induce release of cytochrome c. 
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Deregulation of Apoptosis in Cancer 
 Deregulation of apoptosis plays a critical role in the development of cancer and drug 
resistance.2,99 Apoptosis is highly regulated through the interplay between the proapoptotic and 
antiapoptotic Bcl-2 family of proteins. Numerous studies have pointed at the oncogenic 
capability of proapoptotic Bcl-2 family members.95 A study by Amundson et al100 demonstrated 
a strong correlation between the expression level of Bcl-xL and resistance to chemotherapy. 
Alternatively, based upon the loss-of-function mutagenic studies, it has been rightfully argued 
that antiapoptotic proteins act as tumor suppressors.95 In support of this claim, studies indicated 
that the BIM gene underwent biallelic deletion and promoter hypermethylation in majority of 
mantle cell and Burkitt lymphomas, respectively.101,102 The tumor suppressor activity of 
antiapoptotic proteins is further supported by the increasing evidence that BH3-only proteins get 
activated in response to anticancer drugs.95 For example, it has been suggested that Gleevec 
induces apoptosis through activation of BIM and BAD.103 Another study by Tan et al104 showed 
that paclitaxel induced BIM-dependent apoptosis, which was abrogated by activation of Ras and 
subsequent degradation of BIM in proteasomes. They also argued the potentials benefit of the 
proteasome inhibitor Velcade and paclitaxel combination in the treatment of epithelial tumors.  
 p53 is another regulator of apoptosis that induces cell death in response to DNA breaks, 
hypoxia and proliferative signals.2,99 TP53 is the most commonly mutated gene in cancer cells, 
and studies have established a strong correlation between the wild type p53 status and the 
response to anticancer agents.105 p-53-mediated apoptosis is primarily linked to an increase in the  
transcription of PUMA and NOXA, two BH3-only proteins that interact with antiapoptotic Bcl-2 
family members.95-97 Collectively, these findings articulate the significance of Bcl-2 family of 
proteins in regulating apoptosis in cancer, which can be exploited as targets in future therapies.     
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Autophagy 
Autophagy is an evolutionary conserved degradative mechanism that is required for 
maintaining cellular homeostasis by recycling and turnover of cytoplasmic components. 
Autophagy is associated with various physiological and pathological processes including 
development, aging, cancer, neurodegenerative disorders and infectious diseases.106-108 Cancer 
therapeutics also have the ability to induce autophagy predominantly through interruption of 
EGFR pathway, activation of MAPK signaling pathways and induction of ER stress.107 
Autophagy occurs in three different modes: macroautophagy, microautophagy and 
chaperone-mediated autophagy. Macroautophagy (hereafter referred to as autophagy) is the main 
lysosomal rout for recycling long-lived macromolecules and also organelles, such as 
mitochondria and peroxisomes, when damaged or in excess. It is characterized by formation of 
double-membrane vesicles named autophagosomes around targeted cellular components, which 
directly fuse with lysosomes for enzymatic degradation. Microautophagy involves direct 
engulfment of cytoplasmic components into the lysosome through invagination of the lysosomal 
membrane, whereas chaperone-mediated autophagy is the selective degradation of cytoplasmic 
proteins, which contain a specific motif that can be recognized by lysosomal receptors.106-108 
 Out of 31 autophagy-related genes (ATG) discovered by yeast genetic studies, 18 genes 
are involved in autophagosome formation. Since autophagy is an evolutionary conserved 
process, most of these genes have mammalian homologs with similar functionality.108,109 
Mammalian ATG9 is a trans-membrane protein essential for autophagosome formation 
that has localizes to the trans-Golgi Network (TGN). Upon starvation, BAX-interacting factor-1 
(Bif-1) co-localizes with ATG9 and induces fragmentation of Golgi. The ATG9-containing 
fragments are dispersed in the cytosol and are utilized for autophagosome formation.108 This 
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process requires activation of classIII PI3K (PI3KC3) complex, which consists of PI3KC3, p150, 
Beclin-1, ultraviolet radiation resistance-associated gene (UVRAG) and ATG14L that acts 
upstream of ATG9 trafficking. PI3KC3 forms a complex with p150 adaptor that tethers the 
enzyme to the cytoplasmic membrane. PI3KC3 then binds Beclin-1 that serves as a binding 
partner for UVRAG and ATG14L. Bif-1 binds the complex by interacting with UVRAG. 
Activation of PI3KC3 complex II is regulated by mTOR signaling and is crucial for ATG9 
trafficking and initiation of autophagosome formation.108-110 AMPK and mTORC1 are major 
regulators of autophagy. Under nutrient starvation, AMPK phosphorylates ULK1 on serine 
residues 317 and 777, leading to initiation of autophagy. Under nutrient sufficiency, mTORC1 
phosphorylates ULK1 on serine 757, thus disrupting the interaction between ULK1 and 
AMPK.70 Activated ULK1 is recruited by ATG14L to directly phosphorylate Beclin-1 and 
induce activation of PI3KC3. Activated PI3KC3 phosphorylates phosphatidylinositol (PI) to 
produce phosphatidylinositol 3-phosphate (PI3P) that serves as an anchor for PI3P-binding 
proteins such as ATG18 to bind to form phagophores.110 Recent studies have shown that there 
are two different PI3KC3 complexes: complex I contains PI3KC3, p150, Beclin-1 and ATG14L 
whereas in complex II ATG14L is replaced by UVRAG. Complex I is involved in Formation of 
phagophores while complex II contributes to autophagosome maturation.109,110 The crescent-
shaped phagophores, also known as isolation membranes, are extended to form double-
membrane autophagosomes in a process that involves two ubiquitin-like (UBL) conjugation 
systems. These UBL systems function in a manner that resembles the ubiquitylation process 
involved in protein degradation, which is composed of a ubiquitin-activating enzyme (E1), a 
ubiquitin-conjugating enzyme (E2) and a ubiquitin-protein ligase enzyme (E3).106,111 In the first 
UBL system, ATG12 is activated by E1-like enzyme ATG7, forming an ATG12-ATG7 thioester 
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intermediate before being transferred to ATG10, an E2-like enzyme. In the last step ATG12 
covalently binds ATG5, and ATG12-ATG5 conjugate non-covalently interacts with ATG16L to 
form the final complex. This complex dissociates from the membrane when autophaosome 
formation process is complete. The second UBL system involves modification and incorporation 
of microtubule-associated Protein 1 Light Chain 3 (LC3) into the autophagosome membrane. 
The C-terminal region of LC3 is first cleaved by ATG4 to form LC3-I. E1-like enzyme, ATG7, 
activates LC3-I, which is then transferred to ATG3, an E2 like enzyme. In the final step, LC3-I is 
covalently bound to phosphatidylethanolamine (PE) to form the lipid-protein conjugate LC3-II 
(Figure 8). LC3-II is tightly associated with autophagosomes, and can be used as an autophagic 
marker in mammalian cells. Upon formation, autophagosomes are fused with lysosomes to 
complete protein degradation.106,111  
In addition to bulk degradation of cytoplasmic macromolecules and excessive organelles 
as a result of nutrient deprivation, autophagy can also take part in degradation of mis-folded 
proteins. This process is mediated by the adaptor molecule p62 (sequestosome 1), which 
possesses specific domains to bind both the ubiquitin moiety on the poly-ubiquitinated misfolded 
proteins and the LC3 on the autophagosome membranes. Lysosomal degradation of 
autophagosomes results in a decrease in p62 levels, which makes p62 a suitable marker for 
tracking autophagy in mammalian cells.112 
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Figure 8. Autophagosome formation in mammalian cells. AMPK gets activated in response to 
amino acid starvation, and phosphorylates ULK1. Activated ULK1 subsequently binds ATG14L 
to phosphorylate Beclin-1. Phosphorylation of Beclin 1 activates PI3KC3 in complex I leading to 
production of PIP3 that in turn induces nucleation. Autophagosome formation requires two UBL 
conjugation systems. UBL system 1 produces ATG5-ATG12-ATG16L1 conjugates that attach 
the isolation membranes and facilitate membrane nucleation. UBL system 2 modifies LC3 and 
incorporates the final product, LC3-II, into the autophagosome membrane. The final step in this 
process is fusion of the lysosomes with the autophagosomes that leads to complete degradation 
of autophagosome contents. 
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The Role of Autophagy in Cancer 
The role of autophagy in cancer resembles a double-edged sword; acting as a 
cytoprotective as well as a cytotoxic mechanism.2,113 Radiotherapy and many anticancer drugs 
induce autophagy that seemingly impairs cell death.113 However, quite contrary to its protective 
nature, there is increasing evidence that autophagy acts as a tumor suppressor.113,114 Monoallelic 
loss of beclin1 gene has been shown to promote tumorigenesis associated with chromosomal 
instability and gene amplification, suggesting Beclin1 as a tumor suppressor.115 Another study 
demonstrated that breast cancer cell lines frequently possessed allelic deletion of beclin1gene.116 
Moreover, exogenous expression of Beclin1 in MCF7 cells, which lack the endogenous  Beclin1 
expression, inhibited tumorigenesis.114 Beclin1, a necessary regulator of autophagy, is a novel 
BH3-only protein, which provides a crosstalk point between autophagy and apoptosis. 
Antiapoptotic proteins Bcl-2 and Bcl-xL can bind to Beclin1 and inhibit autophagy whereas 
other proapoptotic BH3-only proteins such as BID, BAD and PUMA can displace Beclin1, and 
induce apoptosis and/or autophagy.2,117    
Autophagy and apoptosis can also crosstalk through of mTOR. Activation of the pro-
survival AKT/mTOR pathway blocks apoptosis as well as autophagy through inactivation of 
ULK1. A role of activated PI3K/AKT/mTOR signaling, which is a common characteristic of 
many cancer cells, in the negative regulation of autophagy provides more evidence for the role of 
autophagy in tumor suppression.2,114    
 Perhaps, the formation of autophagic vesicles in the drug-treated cancer cells could 
initially be a cytoprotective mechanism to degrade the damaged organelles. However, after a 
certain degree of damage, autophagy might induce activation of cell death. Nevertheless, 
whether cells are ultimately destroyed by cytotoxic autophagy requires more investigation.114   
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Endoplasmic Reticulum Stress 
 Proteins targeted for secretory pathway are folded in the lumen of endoplasmic reticulum 
(ER) by chaperones before being transported to Golgi apparatus for final modification and 
secretion. Interruption in this process results in accumulation of unfolded proteins in the lumen 
of ER, referred to as ER stress, and induction of the unfolded protein response (UPR). The UPR 
is a series of actions that collectively reduce the rate of protein synthesis and activate 
transcription factors that enhance function of the ER.118-120 There are three transmembrane 
proteins in the membrane of ER that sense the accumulation of misfolded proteins and trigger the 
UPR: PKR-like eukaryotic initiation factor 2α kinase (PERK), inositol requiring enzyme 1 
(IRE1) and activating transcription factor-6 (ATF6). This sensory mechanism is mediated by the 
chaperone protein glucose-regulated protein of 78 kDa (GRP78), also known as binding 
immunoglobulin protein (BiP), present in the lumen of the ER. Under normal conditions, GRP78 
is bound to the luminal domains of PERK, IRE1 and ATF6 inhibiting their function. Upon ER 
stress occurrence, GRP78 is released to bind to the unfolded protein leading to the activation of 
the three stress sensors. Upon activation, ATF6 is proteolytically cleaved and directly 
translocated into the nucleus to induce the expression of the genes required for the UPR. 
However, activation of PERK and IRE1 is associated with dimerization and subsequent 
autophosphorylation of specific residues on their cytoplasmic kinase domains.118-120 Activated 
IRE1, induces formation of  the transcription activator spliced X-box binding protein (XBP-1) 
through splicing of the XBP-1 messenger RNA whereas PERK phosphorylates the α subunit of 
eukaryotic initiation factor 2 (eIF2α) (Figure 9). Normally, GTP-bound eIF2 binds to methionyl-
transfer RNA and enhances recognition of start codon and is released from ribosomal machinery 
when GTP is hydrolyzed. Phosphorylation of the α subunit of eIF2 inhibits the exchange of GDP 
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for GTP; thus, reducing protein synthesis. Furthermore, activated PERK translationally controls 
the expression of activating transcription factor 4 (ATF4) that induces the expression of variable 
UPR-related genes involved in amino acid metabolism, regulation of oxidative stress and 
apoptosis.119  
 To prevent aggregation of misfolded proteins in the lumen of ER during ER stress, XBP1 
and ATF6 increase expression of proteins that facilitate ER-associated degradation (ERAD).  
ERAD is accomplished by retrotranslocation of misfolded proteins into the cytosol followed by 
ubiquitination and proteasomal degradation. ER stress can also induce autophagy as an alternate 
route for protein degradation.118 The exact mechanism of ER stress-induced autophagy and its 
probable cytoprotective function is not very well elucidated yet, but as previously stated, this 
process is highly regulated by p62, which has the proper domains to bind the ubiquitin moiety of 
the misfolded proteins as well as the LC3 on the autophagosomes.112 
 Severe ER stress can also induce apoptosis, through a process mediated by the interplay 
between Bcl-2 proteins and the UPR components. C/EBP homologous protein (CHOP) is a 
transcription factor that is induced by all three arms of the UPR that can regulate the expression 
of Bcl-2 proteins.120 There is also evidence that CHOP can directly interact and activate certain 
BH3-only proteins such as BIM, thereby directly promoting apoptosis.121 Moreover, It has been 
suggested that ER stress-induced apoptosis occurs through cleavage of caspase 4, a member of 
caspase 1 subfamily that localizes to the ER membrane.121 
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Figure 9. The mechanism of unfolded protein response. Upon accumulation of unfolded 
proteins in the lumen of the ER, the chaperone GRP78 (BiP) is released from the luminal 
domains of PERK, ATF6 and IRE1. These activated transmembrane proteins then trigger 
cascades of events that collectively result in expression of UPR-related genes. Severe ER stress 
can also induce apoptosis through CHOP-mediated changes in the expression of Bcl-2 proteins, 
direct activation of BH3-only proteins by CHOP, or cleavage of ER membrane-bound caspase 4. 
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ER Stress in Cancer 
 The high proliferative and metabolic rates in cancer cells lead to a tumor 
microenvironment characterized by glucose limitation, acidosis, and hypoxia. These conditions 
can result in accumulation of misfolded proteins and induction of UPR.123,124 In fact, an 
increased expression of GRP78 and GRP94 have been observed in many different cancers, 
including cancers of breast, colon and liver. Both of these chaperones have been shown to play a 
role in resisting cell death.124,125 In the same cancers, elevated level of GRP78 has also been 
linked to high pathologic grade, greater risk of recurrence, and poor survival.123 Moreover, 
GRP78 has been shown to confer resistance to chemotherapeutics in multiple tumor type, and its 
knockdown has been demonstrated to sensitize the glioma cells to TMZ.123 Furthermore, In 
support of the role of GRP78 in cancer, studies have indicated that heterozygous GRP78 mice 
had impaired tumor progression, reduced tumor sized and a longer latency period.123,125 In 
addition, other studies have suggested the involvement of ER stress in the induction of 
angiogenesis and metastasis through upregulation of VEGF-A.123,124 This claim is further 
supported by studies in xenograft models where knockdown of GRP78 was associated with less 
invasion and metastasis.123 Surprisingly, GRP78 has also been detected on the surface of highly 
metastatic prostate cancer cells, further supporting its probable function in tumor progression and 
metastasis. The surface GRP78 provides a suitable, more accessible target that can be potentially 
utilized in combination therapies.123 Recent studies from our laboratory have indicated that 
targeting GRP78 is of therapeutic utility for cancer and also for the treatment of bacterial and 
viral infections.126 Collectively, these findings suggest that GRP78 can serve as a potential 
therapeutic target in cancer as well as a novel biomarker to enhance patient treatment in the 
future.123       
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CHAPTER 2: Materials and Methods 
 Materials 
All drugs were purchased from Selleckchem (Houston, TX). Cell lines were obtained from 
ATCC (Bethesda, MD) and were not further validated beyond the validation statements of the 
provider. All media for cell culture (DMEM, RPMI, MEM Alpha, F-12 and Opti-MEM), trypsin-
EDTA, penicillin-streptomycin and 1X Phosphate-buffered saline solution (PBS) were all 
purchased from GIBCOBRL (Invitrogen-GIBCOBRL Life Technologies, Grand Island, NY). 
Fetal bovine serum (FBS) was purchased from HyClone Laboratories, Inc (Thermo Scientific 
Hyclone, South Logan, UT). Bovine serum albumin (BSA), sodium dodecyl sulfate (SDS) and 
glycine were purchased from Fisher Scientific (Fair Lawn, NJ). Trypan blue solution, 
formaldehyde, 6-Diamidino-2-Phenylidole (DAPI), dimethyl sulfoxide (DMSO), rat serum, 
RIPA buffer, bovine insulin, hydrocortisone, crystal violet stain and McCoy’s 5A Medium 
Modified were all obtained from Sigma-Aldrich (St. Louis, MO). Chaps cell extract buffer (10X) 
was obtained from Cell Signaling Technology (Danvers, MA). Anti-Bak, NT polyclonal and 
anti-Bax (active monomer, mAb, 6A7) antibodies were purchased from EMD Millipore 
(Temecula, CA) and Enzo Life Sciences (Farmingdale, NY), respectively. All other primary 
phospho-/total-antibodies were purchased from Cell Signaling Technology (Danvers, MA), 
Santa Cruz Biotechnology (Santa Cruz, CA) and Abcam (Cambridge, MA). Secondary 
antibodies (IRDye 680LT Goat anti-Mouse and IRDye 800CW Goat anti-Rabbit) and Odyssey 
infrared imaging system blocking buffer were obtained from LI-COR Biosciences (Lincoln, NE). 
Alexa Fluor 680 goat anti-mouse IgG, Alexa Fluor 594 goat anti-rabbit IgG, ethidium 
homodimer-1 and calcein-AM were obtained from Life Technologies (Carlsbad, CA). Validated 
siRNAs were purchased from QIAGEN (Valencia, CA).  Recombinant adenoviruses to express 
45 
 
 
 
constitutively activated c-FLIP-s and Bcl-xL and dominant negative caspase 9 were purchased 
from Vector Biolabs, (Philadelphia, PA). Dr. S. Spiegel (VCU) kindly supplied the plasmid to 
express green fluorescent protein-tagged (GFP) human LC3 for vesicle formation assay. All 
other plasmids were obtained from Addgene (Cambridge, MA). The JNK Inhibitor VII, TAT-TI-
JIP was purchased from Calbiochem (EMD Chemicals, Inc. San Diego, CA). All western 
blotting equipments were purchased from BIO-RAD (Hercules, CA). 
Methods 
Cell Culture 
HUH7, HEPG2, HEP3B and HT29 cells were cultured in DMEM supplemented with 5% 
(vol/vol) FBS. HT1080 cells cultured in MEM supplemented with 10% (vol/vol) FBS. HCC38, 
BT474, MCF7 and BT549 cells were cultured in RPMI supplemented with 10% (vol/vol) FBS. 
HCT116, MES-SA, Saos-2 and SKES-1 were cultured in McCoy’s 5a Medium Modified 
supplemented with 10% (vol/vol) FBS. SUM149PT cells were cultured in Ham’s F-12 medium 
supplemented with 5% (vol/vol) FBS, 0.5% (vol/vol) bovine insulin and 0.1% (vol/vol) 
hydrocortisone. All media used in cell culture were also supplemented with 100 µg/ml (1% 
vol/vol) penicillin/streptomycin. Cells were incubated in a humidified atmosphere of 5% CO2 at 
37 °C. For cell viability assays and immunoblotting/immunofluorescence, cells were plated at a 
density of 2 × 104 (per well of a 12-well plate) or 5 × 103 (per well of a 96-well plate) for 24-30 
hours prior to any treatment. 
Drug Treatment 
 Plated cells were treated with desired drugs, which were taken from a 10mM stock 
solution and diluted in DMSO to reach the desired concentration. The maximal concentration of 
vehicle (DMSO) in media was 0.02% (v/v).  
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Assessment of Cell Viability 
  For trypan blue exclusion assays in 12-well plates, the media from each well was 
transferred into a 15ml tube. Attached cells were harvested by trypsinization with trypsin/EDTA 
for 5 minutes at 37°C and then transferred into the corresponding tube. After centrifugation at 
1,200 rpm for 5 minutes the supernatant was removed and the pellet was re-suspended and mixed 
with the vital stain trypan blue. Insertion of trypan blue stain into the cell cytoplasm was used as 
an indicator of cell death. A total of 500 cells from randomly selected fields per experimental 
point were counted using a hemocytometer and a light microscope. The percentage of dead cells 
was expressed as a percentage of the total number of cells counted.  
For live/dead imaging assays in 96-well plates, 100 μL aliquots of 1X PBS containing 
1:2000 dilutions of red fluorescent ethidium homodimer-1 (to detect cells with disrupted cell 
membranes) and green fluorescent calcein-AM (to indicate intracellular esterase activity) was 
added to each well and plates were spun at 800 rpm for 3 minutes to sediment detached dead 
cells onto the plate. Cells were then visualized using a Hermes Wiscan instrument (IDEA Bio-
Medical, Rehovot, Israel) under 10X magnification. The number of viable (green) and dead (red) 
cells were counted manually from several images taken from each well. All viability assays were 
performed in triplicates.    
Western Blot Analysis 
Cells were plated in 60 x 15mm dishes for 24 hours prior to treatment. They were treated 
with the desired concentration of drugs and were incubated for 3, 6, 12 or 24 hours. After 
incubation, cells were lysed and scraped using whole-cell lysis buffer (0.5 M Tris-HCl, pH 6.8, 
2% (w/v) SDS, 10% (v/v) glycerol, 1% (v/v) β-mercaptoethanol, 0.02% (w/v) bromophenol 
blue). Collected samples were boiled for 10 minutes and then loaded onto 8-14% sodium 
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dodecyl sulfate–polyacrylamide gel (SDS-PAGE). Proteins were electrophoretically separated 
and transferred onto 0.45 µm PVDF membrane. The membrane was blocked in Odyssey 
blocking buffer. The membrane was then exposed to desired primary antibodies overnight. After 
removal of the primary antibody, the membrane was then incubated with the corresponding goat 
anti-mouse or rabbit secondary antibody for 2 hours at room temperature. After being washed 
three times with TBST, the immunoblots were visualized using an Odyssey Infrared Imager (LI-
COR Biosciences, Lincoln, NE). 
Infection with Adenovirus 
Cells were plated in 12-well. 24 hours later the media was removed and replaced by 1ml 
of plain medium (lacking FBS and penicillin-streptomycin). Recombinant adenoviruses to 
express constitutively activate c-FLIP-s, Bcl-xL and dominant negative caspase 9 or empty 
vector virus were added at a multiplicity of infection (MOI) of 50. In case of infection in 96-well 
plates, the plain medium containing the adenoviruses was prepared in 1.5 mL-eppendorf tubes 
and then distributed in 100 µL portions into the corresponding wells. The plates were incubated 
for 6 hours and then the plain media was replaced by serum-containing medium (supplemented 
by FBS and penicillin-steptomycin). The cells were then incubated for 24 hours to ensure 
adequate expression of transduced gene products prior to drug exposures. 
Plasmid and siRNA Transfection 
For transfection, 0.5 µg of each plasmid was diluted into 50 µl of Opti-MEM medium 
with no added serum or antibiotic and was incubated in solution for 5 minutes at room 
temperature. Concurrently, 1 µl of Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) was 
diluted into 50 µl of the same medium and was given the same incubation time. After 5 minutes, 
the two solutions were mixed together and incubated at room temperature for 20 minutes. The 
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total mix was added to each well containing 400 µl of the same serum/antibiotic free medium. 
Cells were incubated for 4 hours before equal volume (500 µl) of the appropriate medium 
containing twice the volume of required FBS was added to each well. Cells were then incubated 
for 24 hours before being exposed to desired drugs.  
 Transfection with validated siRNAs was performed in a similar fashion to plasmids with 
all specified siRNAs used at 10nM concentration of the annealed siRNA or the negative control 
(a “scrambled” sequence with no homology to any known genes in human or mouse cell lines).  
Protein Analysis by Immunofluorescence Imaging 
 Cells plated in 96 well plates were treated with desired drugs for certain amount of time 
and were then washed with 1X PBS and fixed in 4% paraformaldehyde for 15 minutes. Fixated 
cells were then blocked with 0.5% triton-X-100 PBS solution supplemented with 10% rat serum 
for 1-2 hours followed by an overnight exposure to 1:500 solution of desired primary antibodies. 
Cells were then washed with PBS and incubated with a 1:2000 dilution of appropriate secondary 
Alexa Fluor anti-mouse or anti-rabbit for 2-4 hours. Fluorescent signals were detected using a 
Hermes Wiscan instrument (IDEA Bio-Medical, Rehovot, Israel). 
 LC3-GFP Vesicle Formation Assay 
 Cells were plated in 4-well glass slides and were transfected with the LC3-GFP plasmid. 
24 hours after transfection, cells were treated with the indicated drugs and were visualized on a 
ZeissAxiovert 200 micoscope (Carl Zeiss, Wake Forest, NC) 6 and 12 hours after the treatment. 
The number of vesicles in 40 cells representing each group was counted, and the average vesicles 
formed in each group was calculated. Colocalization of LC3 to the lysosomal and the 
mitochondrial membranes was assessed using LysoTracker Red DND-99 (Life Technologies, 
#L7528) and MitoTracker Red CMXRos (Life Technologies, #M7512), respectively. 24 hours 
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after drug exposure, the medium was removed and the cells were incubated with plain medium 
(no serum added) containing 25nM of either LysoTracker or MitoTracker probe for 30 minutes 
before being subjected to fluorescent microscopy as previously described. 
Tumor Cell Isolation 
Tumor dissociation was performed using a GentleMACS Dissociator purchased from 
Miltenyi Biotec (San Diego, CA) and was carried out according to the manufacturer’s 
recommended protocol. In short, extracted tumors were cut into small pieces of 2-4 mm and 
were put in a compatible GentleMACS tube with the recommended enzyme mixture. The 
samples were mixed and homogenized by GentleMACS Dissociator and were incubated for 30 
minutes at 37ºC under continuous rotation. After a short centrifugation at 1500 rpm, cells were 
re-suspended and applied to a strainer 30-70 µm (based on cell size). Cells were then grown in 
appropriate cell medium.  
In Vitro and Ex Vivo Colony Formation Assay   
 250-1000 cells/well were seeded in a 6-well plate. A day later, cells were treated with 
appropriate drugs for 24 hours before the drug-containing medium was aspirated and replaced by 
fresh medium. The cells were then cultured for up to two weeks until colonies were observed in 
the control group. The medium was then removed and cells were washed with 1X PBS. The cells 
were then fixed in 100% methanol for 10 minutes. After methanol removal, 0.1% (vol/vol) 
crystal violet stain was added to each well for at least 1 hour. Wells were the washed and number 
of colonies was counted manually. 
 For ex vivo colony formation assay, the tumors were harvested from the nude mice at the 
time of sacrifice and were isolated (as previously described) to obtain a single cell suspension. 
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Cells were then plated 100-10000/well of a 6-well plate. Colonies were permitted to form for 7-
10 days and were fixed, stained and counted. 
Analysis of ROS and RNS Levels 
Cells were plated into a 96-well plate at a density of 10,000 cells/well. 24 hours later, 
cells were incubated with 2’,7’-Dichlorofluorescin diacetate (Sigma, #122M4000V)  at a 
concentration of 10 µM, or 3-Amino-4-(N-methylamino)-2', 7'-difluorofluorescein diacetate 
(DAF-FM DA) at a concentration of 4 µM  for 30 minutes. The DCF-containing medium was 
then removed and cells were washed with 1X PBS before 100 µL of fresh medium containing 
desired drugs was added to the wells. DCFDA/ DAF-FM DA fluorescence signals were detected 
2 and 6 hours after drug exposure using a VICTOR 3 plate reader (PerkinElmer, Waltham, MA). 
Lipid Analysis by Mass Spectrometry 
 Equal number of cells (6 × 106 per well of a 6-well plate) were treated with indicated 
drugs for 6 hours and lipids were extracted. Bioactive lipid levels were quantified at VCU 
Lipidomics/Metabolomics Core Facility by liquid chromatography-electrospray ionization-
tandem mass spectrometry (LC-ESI-MS/MS) with a Shimadzu LC-20AD binary pump HPLC 
system (Shimadzu, Kyoto, Japan) and a 4000 QTRAP (Applied Biosystems, Carlsbad, CA) 
operating in a triple quadruple mode as previously described by Hait et al., 2009.127 
Immunoprecipitation 
 1X Chaps cell extract buffer was prepared according to the manufacturer’s protocol from 
a 10X stock purchased from Cell Signaling Technology (#9852). 24 hours after treatment with 
indicated drugs, cells were lysed in 1X Chaps buffer and scraped off into a 1.5 mL tube. Cells 
were frozen at -80ºC and thawed at room temperature twice, and were spun down at 14,000 rpm 
for 10 minutes. The supernatant was kept and pelleted cell debris was discarded. Concurrently, 
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polystyrene beads (15 µm) (Nalgene, #114218900) were incubated with desired primary 
antibody overnight. Beads were then washed with 1X PBS and were centrifuged at 5000 rpm for 
2 minutes (this step was repeated at least two times). Cell lysates were then added to the 
antibody-coated beads and were incubated overnight at 4ºC on a suitable shaker. 
Immunoprecipitated complexes were collected by centrifugation at 5,000 rpm for 2 minutes, and 
the supernatant was discarded. The pellet from the previous step was washed with 1X Chaps 
buffer at least 3 times to remove any non-specific proteins or unbound antibody. Finally, SDS 
sample buffer (as previously described in western blot analysis) was added to the pellets and 
samples were heated at 100ºC for 5 minutes. Samples were then cooled on ice and were 
subjected to western blot analysis. 
Immunohistochemistry 
 In order to deparaffinize the sectioned tissues, Slides were heated in a Hybaid 
hybridization oven (Thermo Scientific) at 60 ºC for 30 minutes and were then washed with 
xylene substitute (Thermo Scientific, #9990505) three times (10 minutes each). Then, the slides 
were washed for 5 minutes with 100% ethanol (Decon Labs, Inc., #2401), 95% ethanol and 70% 
ethanol, respectively. In the next step, antigen retrieval was carried out using 10mM sodium 
citrate (Sigma, #71497) buffer (pH 6.0). The samples were placed in the buffer, boiled for 15 
minutes and were allowed to cool down in room temperature for 1.5-2 hours. Samples were 
washed three times with 1X PBS and a hydrophobic line was drawn around each specimen using 
an immunopen (Calbiochem, #402176). The samples were incubated for 1 hour with a blocking 
buffer containing 1% BSA (Fisher Scientific, #138191) and 1% goat serum (Life Technologies, 
#16210064) dissolved in TBST. After the blocking buffer was removed, the primary antibodies 
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(1:200) followed by the fluorescent secondary antibodies (1:5000) were added and the slides 
were viewed using the Hermes Wiscan instrument (IDEA Bio-Medical, Rehovot, Israel). 
Tissue Microarray and Immunostaining 
 Human HCC tissue microarrays were purchased from Imgenex Corporation (San Diego, 
CA). Two tissue microarrays were used: one containing 40 primary HCC, 10 metastatic HCC 
and 9 normal adjacent liver samples (Imgenex, IMH-360), the other containing 46 primary HCC 
and 13 metastatic HCC (Imgenex, IMH-318). Antigen retrieval was performed by the 
Department of Pathology, VCU (with thanks to Dr. George Alemara). Immunostaining was 
performed using anti-PDE5 antibody (1:50) or using a mixture of anti PDGFRα and anti-
PDGFRβ (1:50 for each) as described in the previous page under immunohistochemistry. After 
immunostaining slides were stained in Harris hematoxylin solution for 8 minutes and were then 
rinsed in running tap water. In the next step, differentiation was performed in 1% acid alcohol for 
30 seconds and slides were washed again in running tap water. Bluing was done in 0.2% 
ammonia water for 30 seconds to 1 minute and samples were rinsed again in tap water. Samples 
were then counterstained with eosin-phloxine for 1 minute. Samples were then dehydrated 
through 2 five-minute washes with 95% ethanol. Finally, slides were mounted with xylene-based 
mounting medium and were examined by a confocal microscope. 
Tissue Sectioning and H&E Staining 
 All harvested tissues and organs from animals were preserved in Formalin solution 10% 
(Sigma, #SLBH1382V) for 24 hours and were sent out to the Biological Macromolecule Core 
Facility at VCU for paraffin sectioning and H&E staining. Basic histology was performed at the 
VCU Massey Cancer Center Macromolecule Core Facility, sponsored, in part, with funding from 
NCI Cancer Core Grant P30 CA16059. 
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Animal Studies 
 Athymic female NCr-nu/nu mice (National Cancer Institute) weighing 20-25 grams were 
used for the human tumor xenograft studies. Mice were maintained in a pathogen-free vivarium 
approved by the American Association for Accreditation of Laboratory Animal Care and in 
accordance with current regulations and standards of the US Department of Agriculture, the US 
Department of Health and Human Services, and the National Institute of Health. For each 
experiment, ~40 mice (~10 per treatment group) were inoculated each with 5 × 106 cells in 100 
µL (total) of Matrigel (BD, #354234) and 1X PBS (1:1 ratio), subcutaneously either into the 
right rear flank (HUH7, HT29 and HT1080) or into the right fourth mammary fat pad (BT474). 
Seven days after tumor implantation, mice were treated with either vehicle (1:1 ratio of 
Cremophor EL (Sigma, #037K0213) and sterile water) or indicated drugs (dissolved in the same 
solution as the vehicle) for 3-7 days (different for each experiment) by oral gavage. Animals 
were monitored daily and the size (length and width) of each tumor was measured twice a week. 
The tumor volumes were calculated using the formula (L×W2)/2. When the volume of the tumors 
reached >1500 mm3, animals were humanely sacrificed and the tumor, blood and specific organs 
were collected for further studies. Animal survival was plotted on a Kaplan-Meier graph and 
longitudinal statistical assays were performed. 
Multiplex Assay for Cytokine Expression 
 The Bio-Plex Multiplex Reader with associated software and all the related kits and 
reagents were obtained from BIO-RAD (Hercules, CA). The collected blood plasma and tumors 
from the animal experiments were assayed according to the manufacturer’s protocol and with 
BIO-RAD technical assistance. The following Bio-Plex assay plates were used for the 
assessment of human cytokines: Bio-Plex Pro Human Cytokine Group 14-Plex (Y500023JM2), 
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Human CYTO STD GRPII 23-Plex (171D60001), Human CYTO HGF set (171B6008M), 
Human CYTO SDF-1a set (171B6019M), Pro Human Cancer 2 18-Plex (171AC600M) and BP 
Pro TGF-B 3-Plex (171W4001M). 
Multiplex Assay for Signal Transduction Protein Phosphorylation and Expression 
 The following Bio-Plex assay plates were used to examine tumor cell signal transduction 
proteins: Bio-Plex Pro Phosphoprotein magnetic 8-Plex (LQ000041XUYDC4), Bio-Plex Pro 
Phosphoprotein magnetic 15-Plex (LQ000064Q3MJ1). Tumor lysates were assayed according to 
the instructions provided by the manufacturer. 
Data Analysis 
 The effects of various treatments were analyzed using one-way analysis of variance and a 
two-tailed Student’s t-test. Median dose effect isobologram analysis to determine synergism of 
drug interaction was carried out according to the methods of Chou and Talalay151 using the 
CalcuSyn program for Windows (Biosoft). Based on this method, a combination index value of 
< 1.00 indicates synergistic effect, a value of 1.00 indicates additivity, and a value of greater > 
1.00 equates antagonism of action between the drugs. Statistical examination of in vivo animal 
survival data utilized log rank statistical analyses between the different treatment groups. Results 
with a P value of <0.05 were considered statistically significant. Experiments shown are the 
means of multiple individual points from multiple experiments (±SEM). 
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CHAPTER 3: Sildenafil Enhances the Toxic Effects of Sorafenib and Regorafenib in 
Hepatoma and Colon Cancer Cells 
  
Hepatocellular Carcinoma 
 Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer in the world, with 
nearly half a million new cases per year.128-130 Major risk factors for this highly fatal cancer 
include, hepatitis C, hepatitis B, heavy alcohol consumption, hemochromatosis, and 
cirrhosis.128,129 Approximately 80% of the new HCC cases are diagnosed in Africa and Asia, 
mainly due to the hepatitis B virus infection. However, the incidence of HCC has been rising 
rapidly in the western world because of the high prevalence of hepatitis C virus infection.130  
HCC is associated with poor prognosis, and the disease is generally diagnosed late in its 
progression. Therefore, only ~30% of the patients are eligible for curative therapies, including 
tumor resection and liver transplantation.128 Current curative and palliative treatments available 
to the patients vary depending on the stage of the disease.128 They include: 
 1. Surgical resection: the optimal candidates for surgery are non-cirrhotic patients with 
solitary non-metastatic lesions. The risk of recurrence 5 years after surgical resection is more 
than 70%. There are no adjuvant or neoadjuvant therapies available to reduce the recurrence rate. 
 2. Orthotopic liver transplantation: transplantation just like surgery is among the best 
treatments available for the patients diagnosed at early stage of their disease. However, due to a 
shortage of organ donors, nearly 40% of the patients drop out because of tumor progression.128 
3. Radiofrequency ablation (RFA): this method involves application of radiofrequency 
thermal energy locally to the lesions, and induction of necrosis in the tissue surrounding the 
electrode. This treatment is considered safe and effective for the patients ineligible for surgery.128 
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 4. Transarterial chemoembolization (TACE): since the majority of blood supply for the 
hepatic tumors is received through the hepatic artery, injection of chemotherapeutic lipiodol 
emulsion into the hepatic artery presents a feasible approach. The common chemotherapeutics 
used in HCC treatment are adriamycin and cisplatin. However, this method has failed to provide 
any survival advantage.128 
 5. Targeted therapy: due to the frequent deregulation of Raf/MEK/ERK pathway and 
highly vascularized nature of HCC tumors, sorafenib became the first approved form of systemic 
therapy in the treatment of HCC. However, sorafenib produced only a modest effect in a phase II 
trial, where 33% of the patients showed stable disease for a period of 16 weeks.128 Therefore, 
there is a substantial need to improve the clinical outcome of the systemic therapy in HCC.      
Sorafenib 
The bi-aryl urea sorafenib (BAY 43-9006, Nexavar) is an oral multi-kinase inhibitor, 
which inhibits a wide range of targets, including Raf-1, B-Raf (wild type and mutant V600E), 
VEGFR 1/2/3, PDGFRβ, FLT3, RET, and c-Kit with half maximal inhibitory concentration 
(IC50) values in low nanomolar ranges.
130-134 The development cycle of sorafenib (Figure 10) 
took approximately 11 years and it was first approved by Food FDA in December 2005 for the 
treatment of advanced renal cell carcinoma (RCC).132 Sorafenib was later approved as the first 
systemic therapy in advanced HCC as monotherapy with this targeted agent was proven to 
prolong overall survival and delay the progression time.131 Crystallographic studies of sorafenib 
interaction with the kinase domain of B-Raf revealed that the drug bound to the ATP-binding 
pocket, thus blocking substrate binding and phosphorylation.132 The steady-state plasma 
concentrations for Sorafenib in patients who received 800 milligram daily dose of the drug (400 
mg bid) were reached in 7 days, and its toxicity was well tolerated, with adverse effects limited 
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to fatigue, diarrhea and hand or foot skin reactions.131 Sorafenib has an estimated half-life of 25-
48 hours, and is primarily metabolized in the liver via cytochrome P450 (CYP) 3A4.131 In vivo 
and in vitro studies have indicated the ability of sorafenib to interrupt tumor growth and tumor 
microvasculature through anti-proliferative, anti-angiogenic, and pro-apoptotic effects.134  
                          
Figure 10. Chemical structure of sorafenib.131 
 
Colorectal Cancer 
 Colorectal cancer (CRC) is the fourth most prevalent cancer in men and the third most 
common cancer in women worldwide.135 It is also the third most fatal cancer, claiming the lives 
of almost a half a million people annually.136 Surgical resection followed by 5-FU-based 
chemotherapy remains the standard of care for CRC patients.135-137 The current recommended 
adjuvant treatments include: folinic acid + 5-FU + oxaliplatin (FOLFOX) or folinic acid + 5-FU 
+ irinotecan (FOLFIRI) in combination with an anti-EGFR targeted agent such as bevacizumab, 
cetuximab, or panitumumab. The use of anti-EGFR antibodies is not recommended in patients 
with K-Ras mutations.135 Regorafenib is another targeted agent that initially got approved for the 
treatment of metastatic CRC, but its approval was later expanded to include all the 
gastrointestinal stromal tumors (GISTs).138 Lately, the sequential administration of regorafenib 
with standard chemotherapy has been shown to have a promising effect with a manageable level 
of toxicity.139 A phase II clinical study is currently investigating the potency of the combination 
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of regorafenib and FOLFIRI in patients with K-Ras- or B-Raf-mutant CRC after a FOLFOX 
regimen.139 
Regorafenib 
 Regorafenib (BAY 73-4506, Stivarga) is an oral diphenylurea multi-kinase inhibitor that 
is structurally similar to sorafenib. The addition of a fluorine atom in the central phenyl ring 
makes it pharmacologically more potent than sorafenib (Figure 11).139 Just like sorafenib, 
regorafenib have been shown to have an inhibitory effect on a broad range of kinases, including 
Raf-1, B-raf (wild type and mutant V600E), VEGFR 1/2/3, PDGFRβ, FLT3, RET, c-Kit, p38, 
tyrosine kinase with immunoglobulin and epidermal growth factor homology domain-2 (TIE-2), 
an fibroblast growth factor receptor 1 (FGFR1).138-140 One of the major reasons of failure behind 
antiangiogenic therapies is the infiltration of tumor-associated macrophages in the tumor 
microenvironment. These TIE-2-expressing macrophages (TEMs) have been found in a variety 
of tumors and are known to enhance angiogenesis and tumor progression. Therefore, 
regorafenib, a TIE-2 and VEGFR inhibitor, is a more potent inhibitor of angiogenesis than 
sorafenib.140 Regorafenib is metabolized primarily in the liver by CYP3A4, and its half-life has 
been determined to be 20-30 hours.138 The recommended daily dose for regorafenib is 160 mg 
with toxic side effects limited to skin rash, fatigue, hypertension, mucositis and diarrhea.138,139   
                                                
Figure 11. Chemical structure of regorafenib.139 
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Sildenafi Citrate 
  Manufactured by Pfizer, Sildenafil citrate (Viagra) was approved by FDA in March 1998 
as the first orally active drug for the treatment of erectile dysfunction.141 Sildenafil is a potent 
selective inhibitor of cGMP-specific PDE5, and has also been clinically approved for the 
treatment of pulmonary hypertension.142 Sildenafil is rapidly absorbed and reaches maximum 
plasma concentration (Cmax) within 1 hour after dosing. Sildenafil has a terminal half-life of ~4 
hours, and is metabolized by hepatic enzymes CYP3A4 (major) and CYP2C9 (minor).142 The 
adverse effects of sildenafil are limited to headache, flushing and dyspepsia.142 
                                        
Figure 12. Chemical structure of sildenafil.141 
 
Fingolimod 
 Developed by Novartis, fingolimod (FTY720, Gilenya) is a sphingosine 1-phosphate 
(S1P) receptor agonist that was approved by FDA as the first oral agent for the treatment of 
relapsing forms of multiple sclerosis (MS).143,144 Upon entering the blood circulation, fingolimod 
is phosphorylated by sphingosine kinase 2 and converted to the S1P analogous form, S-
fingolimod-phosphate. This active phosphorylated form of the drug is an agonist for the S1P 
receptors.143,144 Further studies indicated that fingolimod acts as a functional antagonist leading 
to S1P receptor internalization and degradation.143,144 Fingolimod causes retention of 
lymphocytes in lymph nodes, thereby reducing the peripheral lymphocytes. It also crosses the 
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blood brain barrier where it further reduces the severity of neuropathological outcomes of 
MS.143,144 Fingolimod is very slowly absorbed and reaches Cmax in 12-24 hours. It has an 
approximate half-life of 9-10 days, and is predominantly metabolized by CYP4F.144 The major 
side effects of fingolimod are bradycardia and slowing of the atrioventricular conduction 
accompanied by fatigue and dizziness.144 
                             
Figure 13. Chemical structure of fingolimod hydrochloride.143 
 
The drug Combination Rationale 
 Prior studies from our laboratory demonstrated that PDE5 inhibitors enhanced the 
toxicities of multiple chemotherapies.145,146 In these studies PDE5 inhibitors, in a NOS-
dependent fashion, were shown to enhance chemotherapy effect through activation of CD95 
receptors, the generation of ROS, and mitochondrial dysfunction. Das et al147 have reported 
similar results, further establishing a link between the activation of CD95 death receptor pathway 
and sildenafil-mediated lethality. Additionally, other studies have indicated that sildenafil 
reversed the ABCB1- and ABCG2-mediated MDR phenotype, leading to an increase in 
intracellular concentration of chemothetrapeutics.148 Inhibition of major efflux pumps could also 
be another contributing factor to the sildenafil-mediated enhanced chemotherapy. Furthermore, 
several studies have reported increased PDE5 expression in multiple cancers, including 
metastatic breast cancer, colon adenocarcinoma, bladder squamous carcinoma, and lung cancer, 
implying a potential role in the cancer progression.147 Collectively, these discoveries suggested 
that PDE5 inhibitors could be repurposed as targeted anti-cancer therapeutics. Therefore, we 
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hypothesized that PDE5 inhibitors would enhance the effect of sorafenib, which is currently 
approved for the treatment of HCC in the clinic. Since regorafenib is a more potent analogue of 
sorafenib approved for the treatment of colon cancer, we later expanded our studies to evaluate 
its interaction with sildenafil to kill colon cancer cells in vivo. 
 Later in our investigations, we also observed an increase in ceramides and S1P levels in 
response to regorafenib. S1P has previously been linked to the induction of colitis-associated 
cancer (CAC), and treatment with FTY720 has been shown to block CAC progression.149,150 
Therefore, we hypothesized that the addition of FTY720 would enhance the lethality of 
regorafenib individually or in combination with sildenafil in killing colon cancer cells.  
Hypothesis 
 Inhibition of PDE5 enhances the toxicities of sorafenib and regorafenib through 
activation of CD95 death receptor signaling, and NOS-dependent generation of ROS and RNS.       
   
Table 1. Hepatic and colon cancer cell lines used in this study. 
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Results 
Sildenafil and sorafenib/regorafenib interact to kill hepatoma cells 
Initial studies examined the dose-response of death receptor CD95 expressing HEP3B 
cells to increasing concentrations of sorafenib (also referred to as SOR in the figures) 
individually and in combination with sildenafil (also referred to as SIL in the figures). Sildenafil 
enhanced sorafenib toxicity in HEP3B cells in a dose dependent fashion (Figure 14A). Sildenafil 
(2 µM) also interacted with sorafenib (2 µM) to kill other hepatoma cells, regardless of whether 
the cells expressed CD95, i.e., HUH7 cells are CD95 null (Figure 14B).   
Regorafenib is a derivative of sorafenib with greater solubility and potency in vitro and in 
vivo than the parent compound. The dose-response of death receptor CD95 null HUH7 cells to 
increasing concentrations of regorafenib (also referred to as REGO/REG in the figures) 
individually and in combination with sildenafil was examined. Similarly to sorafenib, sildenafil 
enhanced regorafenib toxicity in a dose dependent fashion (Figure 15A). Sildenafil (2 µM) also 
interacted with regorafenib (0.5 µM) to kill colon cancer cells (Figure 15B). 
 As previously stated, PDE5, the target of sildenafil, has been shown to be overexpressed 
in multiple cancer types.147 In addition, in prior studies, we had demonstrated that PDGFRα/β 
play an important role in the biology of sorafenib in terms of its toxic combination with other 
therapeutics.152 Knockdown of PDE5 expression enhanced regorafenib toxicity in HUH7 cells 
(Figure 16), and, similarly, knockdown of PDGFRα/β recapitulated the combinatorial effect of 
sorafenib when combined with sildenafil. (Figure 17). 
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A   
                                                                           
B  
                               
                                                              
Figure 14. Sorafenib and sildenafil interact to kill hepatoma cells. (A) HEP3B cells were 
treated with vehicle (DMSO), increasing concentration of sorafenib (0.5-2 µM), and/or Sildenafil 
(2 µM). Cells were isolated 24 hours after drug exposure and viability was determined via trypan 
blue exclusion assay. (B) Hepatoma cells were treated with indicated drugs for 24 hours. Cells 
were then isolated and subjected to trypan blue exclusion assay (n = 3, ± SEM). *P< 0.05 greater 
than vehicle control. 
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B 
                                    
Figure 15. Regorafenib and sildenafil interact to kill hepatoma and colon cancer cells. (A) 
HUH7 cells were treated with vehicle (DMSO), increasing concentration of regorafenib (300-
1500 nM), and/or Sildenafil (2 µM). Cells were isolated 24 hours after drug exposure and 
viability was determined via trypan blue exclusion assay. (B) Colon cancer cells were treated 
with indicated drugs for 24 hours. Cells were then isolated and subjected to trypan blue exclusion 
assay (n = 3, ± SEM). *P<0.05 greater than vehicle control. 
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Figure 16. Knockdown of PDE5 enhances regorafenib toxicity. HUH7 cells were transfected 
with a control scrambled siRNA (siSCR) or three different siRNAs to knockdown expression of 
PDE5. 36 hours after transfection, cells were treated with vehicle (DMSO), or regorafenib (0.5 
µM), or sorafenib (2 µM). 24 hours after drug exposure, cells were isolated and viability 
determined by trypan blue exclusion assay (n = 3, ± SEM). *P<0.05 greater than corresponding 
value in siSCR cells.  
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Figure 17. Knockdown of PDGFRα/β enhances sildenafil toxicity. HEP3B cells were 
transfected with a control scrambled siRNA (siSCR) or two different siRNAs to knockdown 
expression of PDGFRα and PDGFRβ. 36 hours after transfection, cells were treated with vehicle 
(DMSO), or sildenafil (1-2 µM). 24 hours after drug exposure, cells were isolated and viability 
determined by trypan blue exclusion assay (n = 3, ± SEM). *P<0.05 greater than corresponding 
value in siSCR cells.  
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The drug combination activates JNK1/2 and inhibits AKT, mTOR and ERK1/2 
 Treatment of HUH7 cells with the combination of regorafenib (0.5 µM) and sildenafil (2 
µM) reduced the phosphorylation of p38, ERK1/2, AKT (T308) and mTOR (S2448), and 
enhanced phosphorylation of JNK1/2 (Figure 18A). The drug combination also reduced the 
phosphorylation of MEK1 (S218/S222). No obvious change was noted in MEK1 (S298) 
phosphorylation (Figure 18B).  
 Next, we determined if the aforementioned alterations in the phosphorylation of key 
signaling proteins affected the drug combination toxicity. Expression of activated forms of 
MEK1 (caMEK1) or AKT (caAKT) partially suppressed the drug combination lethality whereas 
activated form of mTOR (camTOR) or inhibition of JNK1/2 abolished the drug combination 
toxicity in HEPG2 cells (Figure 19) and HUH7 cells (Figure 20). 
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Figure 18. The REGO+SIL combination alters major signaling pathways. (A) HUH7 cells 
were treated with vehicle (DMSO), regorafenib (0.5 µM), sildenafil (2 µM), or the drug 
combination for 6 hours. Cells were lysed and expression of indicated proteins was determined 
by western blot. (B) HUH7 and HT29 cells plated in 96-well plates were treated with indicated 
drugs (REGO 0.5 μM + SIL 2µM). 6 hours after drug exposure, cells were fixed and probed with 
the indicated antibodies. Images were acquired using a Hermes Wiscan system. 
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Figure 19. Inhibition of JNK1/2 and activation of AKT, mTOR, and MEK1suppresses the 
REGO+SIL combination lethality in HEPG2 cells. HEPG2 cells were transfected with 
plasmids to express either empty vector (CMV), activated MEK1 (caMEK1), activated AKT 
(caAKT), or activated mTOR (ca mTOR). 24 hours after transfection, cells were treated with 
vehicle (DMSO) or regorafenib (0.5 µM) + sildenafil (2 µM) combination. Cell viability was 
assessed 24 hours after drug exposure using a Hermes Wiscan instrument (n = 3, ± SEM). *P< 
0.05 lower than corresponding value in CMV cells. For JNK1/2 inhibition, plated cells were 
treated with the JNK inhibitory peptide (JNK-IP) for 30 minutes before the drugs were added 
accordingly. The viability was determined in a similar way using a Hermes Wiscan instrument.  
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Figure 20. Inhibition of JNK1/2 and activation of AKT, mTOR, and MEK1suppresses the 
REGO+SIL combination lethality in HUH7 cells. HUH7 cells were transfected with plasmids 
to express either empty vector (CMV), activated MEK1 (caMEK1), activated AKT (caAKT), or 
activated mTOR (ca mTOR). 24 hours after transfection, cells were treated with vehicle (DMSO) 
or regorafenib (0.5 µM) + sildenafil (2 µM) combination. Cell viability was assessed 24 hours 
after drug exposure using a Hermes Wiscan instrument (n = 3, ± SEM). *P< 0.05 lower than 
corresponding value in CMV cells. For JNK1/2 inhibition, plated cells were treated with the JNK 
inhibitory peptide (JNK-IP) for 30 minutes before the drugs were added accordingly. The 
viability was determined in a similar way using a Hermes Wiscan instrument.  
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The drug combination induces ER stress 
 A major biological effect of sorafenib is the induction of ER stress/UPR, with reduced 
expression of proteins that have short half-lives such as Mcl-1 and Bcl-xL.153,154 In this study, 
treatment of  HUH7 cells with the combination of regorafenib (0.5 µM) and sildenafil (2 µM) 
increased the phosphorylation of PERK and eIF2α (Figure 21). Inhibition of PERK, ATF4 and 
CHOP in HUH7 cells protected them from the drug combination toxicity (Figure 22).  
The drug combination reduced the levels of Mcl-1 and GRP78. Worthy Of note, the 
drug combination also reduced the expression of ABCB1 and ABCG2 transporters (Figure 21). 
To investigate these observations further in vivo, athymic mice were given vehicle diluent 
(cremophor/ethanol), or sildenafil (5 mg/kg) and sorafenib (25 mg/kg) combination, or sildenafil 
(5 mg/kg) and regorafenib (15 mg/kg) combination by oral gavage once a day. After 5 days of 
treatment, mice were sacrificed, their brains and livers obtained and fixed. The tissues were 
sectioned and subjected to immunohistochemistry and viewed at 10X magnification. In 
accordance with the in vitro observations, the drug combination strongly down-regulated 
GRP78, ABCB1 and ABCG2 in the liver and the brain tissues collected from the athymic mice. 
The drug combination also weakly modulated other chaperones, including GRP94, HSP90 and 
HSP70 (Figure 23).  
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Figure 21. The REGO+SIL combination induces unfolded protein response. HUH7 cells 
were treated with vehicle (DMSO), regorafenib (0.5 µM), sildenafil (2 µM), or the drug 
combination for 6 hours. Cells were lysed and the expression of indicated proteins was 
determined by western blot. 
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Figure 22. Inhibition of the UPR components reduced the REGO+SIL combination 
lethality. HUH7 cells were transfected with a control scrambled siRNA (siSCR) or two different 
siRNAs to knockdown expression of ATF4 and CHOP, or cells were transfected with plasmids 
to express either empty vector (CMV) or dominant negative PERK (dnPERK). 36 hours after 
transfection, cells were treated with vehicle (DMSO), or regorafenib (0.5 µM) and sildenafil (2 
µM) combination. 24 hours after drug exposure, cells were isolated and viability determined by 
trypan blue exclusion assay (n = 3, ± SEM). *P< 0.05 lower than corresponding value in 
siSCR/CMV cells.  
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Figure 23. The REGO/SOR+SIL combination reduced expression of chaperones as well as 
ABCB1 and ABCG2 transporters in vivo. athymic mice were given vehicle diluent 
(cremophor/ethanol), or sildenafil (5 mg/kg) and sorafenib (25 mg/kg) combination, or sildenafil 
(5 mg/kg) and regorafenib (15 mg/kg) combination by oral gavage once a day. After 5 days of 
treatment, mice were sacrificed, their brains and livers obtained and fixed. The tissues were 
sectioned and subjected to immunohistochemistry and viewed at 10X magnification. 
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The drug combination induces the generation of ROS and RNS 
Prior studies from our laboratory demonstrated that PDE5 inhibitors enhanced the 
toxicities of multiple chemotherapies.145,146 In these studies PDE5 inhibitors, in a NOS-
dependent fashion, were shown to enhance chemotherapy effect through activation of CD95 
receptors. PDE5 inhibitors are also known to enhance the levels of reactive oxygen and reactive 
nitrogen species in treated cells.155,156 Treatment of tumor cells with sildenafil and sorafenib 
combination rapidly increased the levels of ROS and RNS (Figure 24A). Inhibition of nitric 
oxide synthase enzymes using L-NG-Nitroarginine Methyl Ester (L-NAME) reduced the drug 
combination-mediated lethality, as did quenching of ROS production by incubating cells with N-
acetyl cysteine (NAC) (Figure 24B). Knockdown of iNOS or eNOS expression suppressed 
killing by the drug combination (Figure 25). Of note, knockdown of iNOS abolished the drug 
combination interaction but did not alter sorafenib toxicity as a single agent, whereas knockdown 
of eNOS significantly reduced sorafenib toxicity. 
As the drug combination increased ROS and RNS levels, and L-NAME and NAC 
protected the cells against the combination-mediated lethality, we determined whether ROS 
regulated CD95 activation. Incubation of cells with NOS inhibitor, L-NAME, suppressed drug-
induced CD95 activation (Figure 26). 
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Figure 24. SOR+SIL combination increases the generation of ROS and RNS. (A) HEPG2 
cells were incubated for 30 minutes with either DCFDA, which is sensitive to oxidation by 
hydroxyl radicals and peroxynitrite directly, and hydrogen peroxide, or DAF-FM DA, which is 
sensitive to oxidation by NO. Cells were then treated with vehicle (DMSO), regorafenib (1 µM), 
sildenafil (2 μM), or the drugs in combination. DCFDA/ DAF-FM DA fluorescence signals were 
detected 2 and 6 hours after drug exposure using a VICTOR 3 plate reader. (B) HEPG2 cells 
were pre-treated with vehicle, L-NAME (1 µM), or NAC (10 mM). Cells were then treated with 
vehicle or sorafenib (2 µM) and sildenafil (2 µM) in combination. 24 hours after drug exposure, 
cells were isolated and viability determined by trypan blue exclusion assay (n = 3, ± SEM). #P < 
0.05 lower than corresponding value in VEH cells. ##P < 0.05 less than corresponding value in 
NAC cells. 
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Figure 25. Inhibition of iNOS and eNOS suppresses SOR+SIL combination toxicity. 
HEPG2 cells were transfected with a control scrambled siRNA (siSCR) or two different siRNAs 
to knockdown expression of iNOS and eNOS. 36 hours after transfection, cells were treated with 
vehicle (DMSO), or sildenafil (2 µM) and sorafenib (2 µM) in combination. 24 hours after drug 
exposure, cells were isolated and viability determined by trypan blue exclusion assay (n = 3, ± 
SEM). #P<0.05 less than corresponding value in siSCR cells.  
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Figure 26. Inhibition of NOS reduces the level of surface CD95 receptors. HEPG2 cells 
plated in a 96-well plate were treated with vehicle or L-NAME (1 μM), then treated with vehicle 
(DMSO), or sildenafil (2 µM) and sorafenib (2 µM) in combination. 6 hours after drug exposure, 
cells were fixed and probed for CD95 expression. Images were acquired using a Hermes Wiscan 
system. 
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The drug combination induces autophagy 
In prior studies, we have shown that sorafenib as a single agent can modestly promote 
increased numbers of autophagosomes.50,152 As previously stated, lysosomal degradation of 
autophagosomes results in a decrease in p62 levels, which makes p62 a suitable marker for 
tracking autophagy in the mammalian cells.112 The level of p62 was reduced 6 hours after HUH7 
cells were treated with the combination of regorafenib (0.5 µM) and sildenafil (2 μM) (Figure 
27) Treatment of cells with the combination of sorafenib and sildenafil increased the numbers of 
autophagosomes and autolysosomes in a greater than additive fashion (Figure 28A). The increase 
in the numbers of autophagosomes was suppressed when cells were pre-treated with L-NAME 
and NAC, establishing a link between the ROS generation and the induction of autophagy 
(Figure 28B). The knockdown of autophagy components ATG5 and Beclin1 reduced the drug 
combination lethality in HEP3B and HUH7 cells (Figure 29).  
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Figure 27. The REGO+SIL combination reduces p62 level. HUH7 cells were treated with 
vehicle (DMSO), regorafenib (0.5 µM), sildenafil (2 µM), or the drug combination for 6 hours. 
Cells were lysed and the expression of p62 was determined by western blot. 
 
 
 
 
 
 
 
 
81 
 
 
 
A 
                   
B 
                    
Figure 28. The SOR+SIL combination induces formation of autophagosomes and 
autolysosomes. (A) HEPG2 cells were transfected with a plasmid to express LC3-GFP-RFP. 24 
hours after transfection, cells were treated with vehicle (DMSO), sorafenib (2 µM), sildenafil (2 
µM), or the combination of both drugs. The number of GFP vesicles (early autophagosomes) and 
RFP vesicles (late autolysosomes) were determined 6 and 24 hours after drug exposure. (B) 
LC3-GFP-RFP transfected cells were pre-treated with L-NAME (1 µM) and NAC (10 mM), and 
then exposed to the combination of sorafenib (2 µM) and sildenafil (2 µM). The number of GFP 
and RFP vesicles were determined 6 and 24 hours after drug treatment (n = 3, ± SEM). *P< 0.05 
lower than corresponding value in control group.  
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Figure 29. Inhibition of autophagy reduced the SOR+SIL combination toxicity. HUH7 and 
HEP3B cells were transfected with a control scrambled siRNA (siSCR) or two different siRNAs 
to knockdown expression of ATG5 and Beclin1. 36 hours after transfection, cells were treated 
with vehicle (DMSO), sorafenib (2 µM), sildenafil (2 µM), or the combination of both drugs. 24 
hours after drug exposure, cells were isolated and viability determined by trypan blue exclusion 
assay (n = 3, ± SEM). *P< 0.05 lower than corresponding value in siSCR cells.  
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The drug combination activates extrinsic and intrinsic apoptosis pathways 
 In our previous studies, we have described how sorafenib can interact with agents that 
generate ROS to facilitate activation of the death receptor CD95.152 In these studies HUH7 cells, 
which lack endogenous CD95 expression, were particularly resistant to the tested sorafenib drug 
combinations. However, in this study, we have found that sorafenib and sildenafil interact to kill 
both CD95 null HUH7 cells and hepatoma cells that express CD95 (HEP3B and HEPG2), 
though the drug combination killing appears to be more efficient in HEP3B and HEPG2 cells 
(Figure 14B). Thus, we next determined whether inhibition of the extrinsic and/or intrinsic 
apoptosis pathways could suppress drug combination-mediated toxicity. Expression of Bcl-xL 
and dominant negative caspase 9 that suppress activation of the intrinsic apoptosis pathway 
protected both HEPG2 and HUH 7 cells (Figure 30). Expression of the caspase 8 inhibitor c-
FLIP-s protected HEPG2 cells, suggesting that the activation of extrinsic apoptosis pathway 
played a role in cell killing. Expression of c-FLIP-s did not alter the cell death response in HUH7 
cells (Figure 30). We further explored signaling by the extrinsic pathway in by looking at 
caspase 8 and FADD levels associated with CD95. Both caspase 8 and FADD rapidly increased 
in response to the drug combination (Figure 31A). In addition, Inhibition of FADD and CD95 
reduced the cell death in HEP3B cells (Figure 31B). Finally, expression of wild type CD95 in 
HUH7 cells enhanced cell killing by sorafenib and the combination of sorafenib and sildenafil 
whereas expression of a mutant CD95, lacking the specific tyrosine residues required for 
activation, did not alter cell death (Figure 32). 
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Figure 30. The SOR+SIL combination activates extrinsic and intrinsic apoptosis pathways. 
HUH7 and HEPG2 cells were infected with recombinant adenoviruses to express empty vector 
(CMV), dominant negative caspase 9 (dn casp 9), Bcl-xL, or c-FLIP-s. 24 hours after infection 
cells were treated with vehicle (DMSO), sorafenib (2 µM), sildenafil (2 µM), or the combination 
of both drugs. 24 hours after drug exposure, cells were isolated and viability determined by 
trypan blue exclusion assay (n = 3, ± SEM). #P< 0.05 lower than corresponding value in CMV 
cells.  
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Figure 31. The SOR+SIL combination activates CD95 death receptors. (A) HEPG2 cells 
were treated with vehicle (DMSO), sorafenib (2 µM), sildenafil (2 µM), or the combination of 
both drugs. 6 hours after treatment, cells were lysed and prepared for immuoprecipitation (IP) of 
CD95. After IP, immunoblotting was performed to determine the levels of caspase 8 and FADD 
in the immunoprecipitate. Total levels of CD95 and GAPDH in the lysates are also presented. 
(B) HEP3B cells were transfected with a control scrambled siRNA (siSCR) or two different 
siRNAs to knockdown expression of FADD and CD95. 36 hours after transfection, cells were 
treated with vehicle (DMSO), sorafenib (2 µM), sildenafil (2 µM), or the combination of both 
drugs. 24 hours after drug exposure, cells were isolated and viability determined by trypan blue 
exclusion assay (n = 3, ± SEM). #P< 0.05 lower than corresponding value in siSCR cells.  
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Figure 32. CD95 expression enhances SOR+SIL combination toxicity in HUH 7 cells. 
HUH7 cells were transfected with plasmids to express either empty vector (CMV), a plasmid to 
express CD95-GFP, or a plasmid to express CD95-GFP-Y232F Y291F. 24 hours after 
transfection, cells were treated with vehicle (DMSO), sorafenib (2 µM), sildenafil (2 µM), or the 
combination of both drugs. 12 hours after drug treatment, cell viability was assessed using a 
Hermes Wiscan instrument (n = 3, ± SEM). *P< 0.05 greater than corresponding value in CMV 
cells. 
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The drug combination increases the ceramide levels 
 Prior reports from our group have shown that sorafenib can increase the levels of 
ceramides in hepatoma cells.152 In accordance with our previous findings, regorafenib and 
sildenafil treatment increased the levels of multiple ceramide and dihydro-ceramides in HUH7 
cells (Figure 33). Regorafenib also increased the levels of sphingosine-1 phosphate (Figure 34). 
The approved multiple sclerosis drug FTY720 (fingolimod, Gilenya) inhibits the production of 
S1P as an active site inhibitor of sphingosine kinase 1 and 2.143,144 Treatment of cells with low 
clinically relevant concentration s of FTY720 suppressed the ability of regorafenib to increase 
S1P (Figure 34). 
 We next determined if FTY720 can enhance the toxicity of the combination of 
regorafenib and sildenafil. Our data indicated that the addition of FTY720 to the drug 
combination significantly increased percentage cell death in HUH7 and HT29 cells (Figure 35).    
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Figure 33. The REGO+SIL combination increases ceramide levels. HUH7 cells were treated 
with vehicle (DMSO), regorafenib (0.5 µM), sildenafil (2 µM), or the drug combination for 6 
hours. Cells were then isolated and bioactive lipids were extracted. Multiple bioactive lipids 
were analyzed using GC/MS techniques (n=2 in triplicate ±SEM). *P< 0.05 greater than 
corresponding value in VEH cells. 
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Figure 34. Regorafenib increases S1P levels. HUH7 cells were treated with vehicle (DMSO) or 
regorafenib (0.5 µM), and/or Fumonisin B1 (25 μM) or FTY720 (50 nM). 6 hours after 
treatment, cells were isolated and bioactive lipids were extracted. S1P levels were analyzed using 
GC/MS techniques (n=2 in triplicate ±SEM). *P< 0.05 greater than corresponding value in VEH 
cells. #P< 0.05 lower than corresponding value in regorafenib-treated VEH cells. 
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Figure 35. FTY720 enhances REGO+SIL combination-mediated toxicity. HUH7 and HT29 
cells were treated with vehicle (DMSO), regorafenib (0.5 µM) and sildenafil (2 µM) 
combination, FTY720 (50 nM), or the combination of all three drugs. 12 hours after drug 
treatment, cell viability was assessed using a Hermes Wiscan instrument (n = 3, ± SEM). *P< 
0.05 greater than corresponding value in SIL+REGO cells. 
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Sildenafil interacts with sorafenib/regorafenib to kill tumor cells in vivo 
 We next determined whether sorafenib/regorafenib interacted with sildenafil in vivo to 
kill tumor cells. Initial studies examined the ex vivo plating efficiency of tumor cells treated in 
vivo with regorafenib and sildenafil. Treatment of cells with sildenafil (5 mg/kg) and regorafenib 
(25 mg/kg) in vivo caused a reduction in ex vivo plating efficiency of isolated tumor cells 
following drug exposure; thus the long-term colony forming ability of the drug-treated cells was 
reduced beyond that achieved due to the proximal anti-tumor effects of the individual drugs 
(Figure 36A). We then performed additional studies using preformed HUH7 tumors (~150 mm3). 
In our prior studies, HUH7 cells had a significantly greater tumorigenic potential than either 
HEPG2 or HEP3B cells to grow in an athymic mouse. Due to the lack of CD95 expression in 
these cells, the relative effect of the drug combination might be less efficient even though data 
from previous figure (Figure 36A) argues than interaction between the two drugs occurs in vivo. 
Transient treatment of animals with sildenafil (5 mg/kg) did not alter tumor growth whereas 
treatment with sorafenib (25 mg/kg) caused a non-significant trend towards reduced growth. 
Combined treatment of mice with both drugs for 3 days caused a significant reduction in HUH7 
tumor growth (Figure 36B). 
 Based on the data from FTY720 interaction with the drug combination (Figure 37), we 
then determined if FTY720 interacted with regorafenib and the combination of regorafenib and 
sildenafil to kill HT29 cells in vivo (Figure 37). FTY720 (0.05 mg/kg) as a single agent, had a 
modest effect on reducing tumor growth but did cause a modest significant increase in overall 
survival (Figure 37 and 38). Surprisingly, we found that a transient 7-day treatment of HT29 
tumors with regorafenib and FTY720 or with regorafenib (25 mg/kg) and sildenafil (5 mg/kg) 
and FTY720 caused tumors exposed to FTY720 to re-grow at a much faster rate after cessation 
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of drug treatment than either regorafenib treatment alone or treatment with regorafenib and 
sildenafil (Figure 37). The growth of tumors treated with the combination of regorafenib and 
sildenafil was profoundly reduced both during and for many weeks following the cessation of 
treatment, which was reflected in a significant increase in animal survival (Figure 38). 
 Morphological examination of the tumors in situ in the mouse flank (pictures were 
chosen with tumors in each condition at the same approximate volume) demonstrated that the 
tumors treated with FTY720 exhibited a more vascularized appearance on their surface (Figure 
39). H&E staining of sectioned tissues of multiple organs collected from the vehicle group and 
the group that received the combination of regorafenib and sildenafil indicated that the drug 
combination did not damage the normal tissues (Figure 40). 
 In addition to previous in vivo studies, we also collected portions of the tumors from each 
group at the time of sacrifice. The tumors were digested and single cells were plated to determine 
the ex vivo plating efficiency of cells. Treatment of tumors with FTY720 individually, that had a 
marginal effect on tumor growth and animal survival, significantly reduced ex vivo plating 
efficiency (Figure 41). Regorafenib as a single agent did not alter ex vivo colony formation that 
correlated with our tumor growth and survival findings and with the clinical data where 
regorafenib has only a ~1% response rate. The reduced plating efficiency of tumors treated with 
regorafenib and sildenafil correlated with suppressed tumor growth and increased animal 
survival. 
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Figure 36. The drug combination suppresses tumor growth in vivo. (A) HUH7 and HCT116 
tumors were formed in the flank of athymic mice (~150 mm3). Animals were treated with vehicle 
(cremophor/ethanol), sildenafil (5 mg/kg), regorafenib (25 mg/kg), or the combination. Tumors 
were isolated, digested and single cells were plated. Colonies were permitted to form in 7-10 
days. Colonies were then fixed, stained and counted. Survival value in the vehicle group was 
defined as 100% (n=6 ±SEM). #P< 0.05 lower than corresponding value in regorafenib-treated 
cells. (B) HUH7 tumors were formed in the flank of athymic mice (~150 mm3). Animals were 
treated with vehicle (cremophor/ethanol), sildenafil (5 mg/kg), sorafenib (25 mg/kg), or the 
combination for 3 days. Tumor volumes were measure 7 and 14 days after the start of the 
treatment. (n=2 studies, 8 animals per group ± SEM). #P< 0.05 less than sorafenib-treated cells. 
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Figure 37. Regorafenib interacts with sildenafil to kill HT29 cells in vivo. HT29 tumors were 
formed in the flank of athymic mice (~30 mm3). Animals were treated with vehicle 
(cremophor/ethanol), sildenafil (5 mg/kg) and regorafenib (25 mg/kg), FTY720 (0.05 mg/kg) or 
the combination of all drugs for 7 days. Tumor volumes were measured every 4 days after the 
end of the drug treatment (n = 2 studies, 8 animals per group ± SEM). 
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Figure 38. Combination of regorafenib and sildenafil significantly increased the survival 
time. Kaplan Meier survival plot of animals treated in previous study (Figure 39); animals were 
humanely sacrificed when tumor volumes exceeded 1500 mm3. 
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Figure 39. HT29 tumors pictured between days 15-30. Representative images of tumors from 
each group were taken between days 15 and 30 when tumors were of approximately the same 
volume. Tumors from the FTY720-treated groups have a more vascularized appearance.  
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Figure 40. The REGO+SIL combination did not damage the normal tissue. Vital organs 
were collected from the mice that received the vehicle (cremophor/ethanol) or the combination 
of regorafenib and sildenafil for 7 days. Tissues were sectioned and H&E stained, and were 
examined under 10X magnification. 
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Figure 41. The REGO+SIL combination significantly reduced the ex vivo plating efficiency. 
HT29 tumor cells, at the time of sacrifice, were isolated and gently digested to obtain a single 
cell suspension of tumor cells. Cells were plated as single cells 100-10,000 per well of a 6-well 
plate. Colonies were permitted to form in 7-10 days. Colonies were then fixed, stained and 
counted, and plating efficiency was determined (n=8 ± SEM). #P< 0.05 lower than 
corresponding value in VEH and REGO-treated cells.  
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The drug combination alters the cytokine expression levels in mouse plasma 
 Based on our in vivo findings, we determined the expression levels of human cytokines in 
mouse plasma and activity of signal transduction proteins within the established tumor itself. 
Regorafenib and sildenafil exposure for 7 days decreased the plasma levels of bFGF and GM-
CSF but significantly increased PDGFbb (Figure 42A). Treatment of tumors with FTY720 for 7 
days increased plasma levels of FAS-L (Figure 42B). For a number of cytokines, including 
endoglin, IL-6, VEGF-A/C/D, endopoietin 2, and EGF the plasma level declined in vehicle 
control treated tumors over 7 days of growth, which was associated with a mean of 
approximately seven fold increase in tumor volume (Figure 42B-F). In this respect, treatment of 
tumors with FTY720 or with regorafenib and FTY720 combination prevented the decline in 
plasma cytokine levels that were observed in mice with vehicle control treated tumors at day 7 
(Figure 42B-G). For tumors exposed to regorafenib and sildenafil, the expression of pro-growth, 
pro-angiogenic, and pro-invasion cytokines was either unchanged compared to the vehicle 
control or was significantly reduced (Figure 42C-G). 
 Additionally, treatment of tumors with regorafenib and FTY720 combination increased 
the expression of pro-growth/pro-angiogenic/pro-invasion cytokine endoglin, which enhances 
TGFβ signaling (Figure 42G).  as treatment of tumors with FTY720 caused an increase in 
endoglin expression, which would enhance TGFβ receptor family as well as integrin signaling, 
we determined whether the toxicity of regorafenib and FTY720 combination was enhanced in 
vitro using TGFβ inhibitor LY2157299 (Galunisertib). Our data indicated that the inhibition of 
TGFβ receptor 1 signaling in a dose-dependent fashion significantly enhanced the toxicity of 
regorafenib+FTY720 combination (Figure 43). 
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Figure 42. The drug combination alters the cytokine expression levels in mouse plasma. (A-
G) HT29 tumors (~30 mm3) were formed in the flanks of athymic mice. Aliquots (~75 μL) of 
mouse blood were obtained in a heparin/EDTA coated Eppendorf tube. Animals were then 
treated with vehicle diluent (cremophor/ethanol), sildenafil (5 mg/kg) and regorafenib (25 
mg/kg), FTY720 (0.05 mg/kg) or the combination of all drugs for 7 days. Data in part A are 
vehicle control and the combination of regorafenib and sildenafil tumor data. After 7 days 
aliquots of mouse blood were obtained again. Clarified mouse plasma free of blood cells was 
then subjected to multiplex assays in a BIO-RAD MAGPIX system to determine the expression 
of the indicated cytokines before and following treatment (n=2 studies, 8 animals per group ± 
SEM). *P< 0.05 greater than day 0 pre-treatment value. **P< 0.05 greater than day 7 vehicle 
control value. #P< 0.05 less than day 0 pre-treatment value. ##P< 0.05 less than day 7 vehicle 
control value. лP< 0.05 less than day 7 regorafenib treatment value.   
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Figure 43. Inhibition of TGFβ signaling enhances the toxicity of regorafenib and FTY720 
combination. HT29 and HCT116 cells were treated with vehicle (DMSO), regorafenib (0.5 μM) 
and FTY720 (50 nM) combination, LY2157299 (2, 6 μM), or the combination of all drugs as 
indicated. 12 hours after drug treatment, cell viability was assessed using a Hermes Wiscan 
instrument (n = 3, ± SEM). *P< 0.05 greater than corresponding value in REGO+FTY cells. 
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The drug combination alters multiple signaling pathways 
 We also collected tumor and blood materials at the time of humane sacrifice of the mice 
from our HT29 experiment. Most notably the expression of growth factors bFGF and PDGFbb 
were elevated and the expression of GM-CSF reduced (Figure 44A). This was associated with 
increased AKT activity and reduced p70S6K phosphorylation (Figure 44B). Changes in receptor 
phosphorylation or transcription factor phosphorylation were not significant (Figure 44C and D). 
Based on our data showing that drug-treated tumors had stable high EGFR phosphorylation, 
expressed more FGF and had higher AKT activity, we determined the impact of the inhibitors of 
EGFR (lapatinib), FGFR (BGJ398), and AKT (MK2206) on the toxicity of regorafenib and 
sildenafil combination. Inhibition of either AKT or EGFR enhanced the lethality of regorafenib 
and sildenafil combination (Figure 45). 
 We then determined the activities of multiple signal transduction pathways/proteins in 
tumors collected 7 days after the start of the treatment. Treatment of HUH7 and HT29 tumors 
with the combination of regorafenib and sildenafil reduced plasma levels of FGF and GM-CSF 
and increased the levels of PDGFbb (Figure 42A and 46A). Regorafenib and sildenafil treatment 
also reduced the expression of multiple tumor growth factors in the blood of mice carrying 
HUH7 tumors (Figure 46B). In both HUH7 and HT29 tumors, the drug combination caused 
activation of AKT though total p70S6K phosphorylation was reduced in both tumor types 
(Figure 48C). These findings were associated with reduced PDGFRβ phosphorylation and 
decreased NFκB activity (Figure 46D and E). Based on the biomarkers for activated 
compensatory survival pathways, the candidates for third drug combinations include AKT 
inhibitors, FGFR inhibitors, and EGFR inhibitors. The impact of such inhibitors on the toxicity 
of regorafenib and sildenafil were validated in vitro (Figure 45). 
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Figure 44. The drug combination alters multiple signaling pathways in tumor cells. (A-D) 
HT29 tumors isolated from the vehicle control or the combination of regorafenib and sildenafil- 
treated mice collected at the time of sacrifice were subjected to multiplex assays in a BIO-RAD 
MAGPIX instrument to determine the expression of cytokines in plasma and the phosphorylation 
of the indicated signal transduction proteins (n=8 ± SEM). ~P< 0.05 greater than vehicle control 
value. #P< 0.05 less than corresponding vehicle control value. 
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Figure 45. AKT, FGFR and EGFR inhibitors enhance the REGO+SIL combination 
lethality. HT29 cells were treated with vehicle (DMSO), regorafenib (0.5 μM) and sildenafil (2 
μM) combination, lapatinib (1 μM), MK2206 (1 μM), BGJ398 (1 μM), or the combinations as 
indicated in the figure. 12 hours after drug treatment, cell viability was assessed using a Hermes 
Wiscan instrument (n = 3, ± SEM). *P< 0.05 greater than corresponding value in REGO+SIL 
group. 
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Figure 46. Multiplex analysis of tumors collected at the time of sacrifice. (A-E) HT29 and 
HUH7 tumors isolated from the vehicle control or the combination of regorafenib and sildenafil- 
treated mice collected at the time of sacrifice were subjected to multiplex assays in a BIO-RAD 
MAGPIX instrument to determine the expression of cytokines in plasma and the phosphorylation 
of the indicated signal transduction proteins (n=8 ± SEM). ~P< 0.05 greater than vehicle control 
value. #P< 0.05 less than corresponding vehicle control value. 
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Discussion 
 Our data demonstrated that PDE5 inhibitor sildenafil and sorafenib/regorafenib interact to 
kill a genetically diverse set of hepatic and colon cancer cells in vitro and in vivo. Prior studies 
from our laboratory demonstrated that PDE5 inhibitors enhanced the toxicities of multiple 
chemotherapies.145,146 In these studies PDE5 inhibitors, in a NOS-dependent fashion, were shown 
to enhance chemotherapy effect through activation of CD95 receptors, the generation of ROS, 
and mitochondrial dysfunction. In addition, in prior studies, we had demonstrated that 
PDGFRα/β play an important role in the biology of sorafenib and regorafenib in terms of its 
toxic combination with other therapeutics.152 In agreement with our previous studies, knockdown 
of PDE5 recapitulated the combinatorial effect of a PDE5 inhibitor when combined with 
sorafenib whereas knockdown of PDGFRα/β recapitulated the combinatorial effect of sorafenib 
when combined with sildenafil. Thus, we further validated that the inhibition of PDE5 and 
PDGFRα/β does indeed play a major role in the induction of cell death by the drug combination.  
PDE5 inhibitors are known to enhance cGMP and NO levels; inhibition of NOS enzymes by L-
NAME reduced the drug combination-mediated toxicity. 
 In our previous studies, we had described how sorafenib can interact with agents that 
generate ROS to facilitate activation of the death receptor CD95.152 In these studies HUH7 cells, 
which lack endogenous CD95 expression, were particularly resistant to the tested sorafenib drug 
combinations. However, in this study, we have found that sorafenib and sildenafil interact to kill 
both CD95 null HUH7 cells and hepatoma cells that express CD95 (HEP3B and HEPG2), 
though the drug combination killing appears to be more efficient in HEP3B and HEPG2 cells. In 
order to further validate the role of death receptor CD95 signaling in drug combination-mediated 
cell death, we transfected HUH7 cells with a plasmid expressing wild type CD95, and managed 
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to immensely increase the combination-mediated lethality in these cells. Moreover, in cells 
expressing CD95, inhibition of both extrinsic and intrinsic apoptosis pathways suppressed the 
drug combination toxicity whereas in HUH7 cells cell death was due to the activation of intrinsic 
pathway. We also showed that activation of CD95 receptors was suppressed by inhibition of 
NOS enzymes. Studies by others have shown that nitrosylation of CD95 at its regulatory tyrosine 
residues inhibit CD95 signaling.157 However, others have argued that NO signaling and 
activation of CD95 can cooperate to induce cell death.158  
 The drug combination also increased the numbers of autophagosomes and autolysosomes 
in a time dependent fashion that was inhibited by incubation of the cells with L-NAME and 
NAC. Inhibition of autophagy reduced cell death caused by the drug combination. NO signaling 
has been linked by others to the regulation of autophagy as in some primary non-transformed 
cells NO can inhibit autophagy by inhibiting JNK signaling.159,160 However, in some transformed 
cells NO signaling can promote autophagy in an mTOR-dependent fashion, which seems to play 
a role in tumor cell death.161,162 In this study, we demonstrated that the drug combination 
inactivated mTOR, and expression of an activated mTOR suppressed killing. Activation of the 
JNK pathway played a key role in the drug combination-mediated lethality. Therefore, NO 
signaling plays a role in de-repressing a brake on toxic autophagy (mediated by mTOR) as well 
as promoting activation of CD95-mediated apoptosis.  
 The drug combination rapidly increased the levels of ROS and RNS. Inhibition of NOS 
enzymes almost abolished cell killing caused by the drug combination whereas quenching of 
ROS by NAC was partially protective. In accordance with these findings, knockdown of iNOS 
and eNOS was also protective. One important mechanism by which NO is inactivated is by 
reaction with the superoxide anion (O2
-).163 Compared to non-transformed cells, tumor cells 
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generate considerably greater amounts of O2
-.164 As mentioned before, NOS activity depends on 
several cofactors, including NADPH and BH4. BH4 plays a critical role in NOS activity. Small 
ratio of BH4 relative to its oxidized form, BH2, causes NOS uncoupling, leading to production 
of ROS and RNS rather than NO, a phenomenon commonly observed in cancer cells.87,89 Thus, 
whereas sildenafil is often associated with reduced oxidative stress in non-transformed cells, it 
promotes oxidative stress in tumor cells.156 The reaction of NO with O2
- forms the most potent 
oxidant peroxynitrite (ONOO-).165 Peroxynitrite causes oxidative damage and S-nitrosylation of 
proteins, lipids, and DNA.166 Nitrosative stress by ONOO- has been implicated in DNA 
breakage, followed by PARP and ATM/ATR activation.167 Further studies will be required to 
determine whether ATM/ATR signaling plays any role in the regulation of apoptosis/autophagy 
pathways and signal transduction pathways. 
 As previously stated, a major biological effect of sorafenib is the induction of ER 
stress/UPR, with reduced expression of proteins that have short half-lives such as Mcl-1 and Bcl-
xL.153,154 In agreement with these reports, the drug combination in this study also induced UPR 
as the levels of phospho-PERK and phospho-eIF2α rapidly increased within 6 hours after drug 
exposure. Of note, in addition to a reduction in Mcl-1 and GRP78 levels, the levels of multiple 
other chaperones such as GRP94, HSP90 and HSP70 as well as the ABC transporters ABCB1 
and ABCG2 were significantly reduced in vivo as shown by immunohistochemistry data. Further 
investigations from our laboratory indicated that the combination of sildenafil and 
regorafenib/sorafenib reduced the levels of a wide range of surface receptors, including the 
receptors involved in viral and bacterial infections, which further highlighted the therapeutic 
value of chaperones, most notably GRP78, in treatment of multiple human diseases.126,168 
Inhibition of the UPR components such as PERK, ATF4 and CHOP significantly reduced the 
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drug combination lethality. Prior studies by our colleagues had reported that sorafenib treatment 
induced ER stress and activation of caspase 2 and 4, which directly induce apoptosis.153 The role 
of ER-specific caspase activation was not explored in this study. However, our data argues that 
the ER stress is involved in the drug combination-induced cell death. 
 Based on our encouraging in vitro data, we moved our studies forward using several 
animal model systems in athymic mice. Short-term exposure to sildenafil and regorafenib killed 
tumor cells as judged by ex vivo colony formation assays. Long-term exposure to sildenafil and 
sorafenib suppressed HUH7 tumor growth over several weeks. This is of note as HUH7 cells, 
which lack CD95, would be predicted based on in vitro data to respond relatively poorly to the 
drug combination. Similarly, the growth of HT29 tumors treated with the combination of 
regorafenib and sildenafil was profoundly reduced both during and for many weeks following 
the cessation of treatment, which was reflected in a significant increase in animal survival. The 
drug combination anti-tumor activity in vivo is likely an amalgamation of a direct anti-tumor cell 
killing effect by the drug combination and increased tumor vasculature permeability caused by 
the actions of sildenafil on endothelial cells.169 During our in vitro studies, we also noted an 
increase in ceramides and S1P in response to regorafenib treatment. S1P has previously been 
linked to the induction of colitis-associated cancer (CAC), and treatment with FTY720 has been 
shown to block CAC progression.149,150 Our in vitro studies indicated that the addition of 
FTY720 to the drug combination significantly enhanced cell death in HT29 and HUH7 cells. 
Therefore, we determined whether FTY720 could replicate the same effect in the mouse models. 
To our surprise, FTY720-treated tumors resulted in an unexpected stronger re-growth of tumors 
after cessation of drug treatment than the tumors treated with regorafenib or the regorafenib and 
sildenafil combination. Images taken from the tumors indicated that the FTY720-treated tumors 
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had a more vascularized appearance. Multiplex analysis of cytokines in the blood of animals 
treated with FTY720 collected at day 7 revealed a significant increase in angiogenic factors, 
including VEGF-A, VEGF-D and angiopoietin. Additionally, treatment of tumors with 
regorafenib and FTY720 combination increased the expression of pro-growth/pro-
angiogenic/pro-invasion cytokine endoglin, which enhances TGFβ signaling. Thus, we 
determined whether the toxicity of regorafenib and FTY720 combination was enhanced in vitro 
using TGFβ inhibitor LY2157299 (Galunisertib). Our data indicated that the inhibition of TGFβ 
receptor 1 signaling in a dose-dependent fashion significantly enhanced the toxicity of 
regorafenib and FTY720 combination.  
 Based on our multiplex analysis data from the collected tumors and blood from the 
animals at the time of sacrifice, we found that drug combination-treated tumors had stable high 
EGFR phosphorylation, expressed more FGF and had higher AKT activity. Consequently, we 
determined the impact of the inhibitors of EGFR (lapatinib), FGFR (BGJ398), and AKT 
(MK2206) on the toxicity of regorafenib and sildenafil combination. Inhibition of either AKT or 
EGFR enhanced the lethality of regorafenib and sildenafil combination. Thus, the activation of 
AKT and EGFR in response to the regorafenib and sildenafil combination seems to be the major 
compensatory survival pathways. 
 As the drugs used in this study are all FDA approved agents, our data argue for further 
determination as to whether sorafenib/regorafenib and sildenafil can interact in the same fashion 
in the clinic. Recently, a clinical trial in Massey Cancer Center (NCT02466802) evaluating the 
combination of regorafenib and sildenafil in all solid tumors has opened. 
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Figure 47. Proposed mechanism of the SOR/REGO+SIL combination-mediated cell death. 
The drug combination inhibited PDE5, thus increasing the levels of ROS and RNS in a NOS-
dependent fashion. The generation of ROS was shown to activate death receptor CD95 signaling. 
The drug combination also inhibited ERK1/2 and AKT, and activated JNK1/2. Inhibition of 
AKT/mTOR pathway activated a toxic form of autophagy. In addition, the drug combination 
induced the UPR; resulting in an increase in transcription of CHOP. The induction of ER stress 
by the drug combination was shown to be involved in mediating cell death.(Guide:       represents 
explored pathways,        represents unexplored but feasible pathways) 
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Conclusion 
 Collectively, our data from this study demonstrated that sorafenib/regorafenib interacts 
with sildenafil to kill a genetically diverse set of hepatic and colon cancer cells in vitro and in 
vivo in a process that involves ER stress, autophagy, and intrinsic and extrinsic apoptotic 
pathways. The drug combination rapidly increased the levels of ROS and RNS in a NOS-
dependent fashion. Incubation of cells with L-NAME, a NOS inhibitor, suppressed drug 
combination-induced CD95 activation. Long-term exposure to sildenafil and sorafenib 
suppressed HUH7 tumor growth over several weeks. Similarly, the growth of HT29 tumors 
treated with the combination of regorafenib and sildenafil was profoundly reduced both during 
and for many weeks following the cessation of treatment, which was reflected in a significant 
increase in animal survival. By applying multiplex technology, we were able to predict and 
validate various signaling biomarkers with AKT and EGFR being identified as major 
compensatory survival responses to the drug combination. 
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CHAPTER 4: Ruxolitinib and EGFR Inhibitors Interact to Kill Breast Cancer Cells in a 
Synergistic Fashion 
Breast Cancer 
Breast cancer is the leading cause of death in women worldwide. According to World 
Health organization (WHO), in 2012 breast cancer accounted for 23% of all cancer deaths across 
the globe.170 The same year in the US, 200,000 new cases were diagnosed with about 40,000 of 
the patients losing their lives, making it the second deadliest disease among women after lung 
cancer.171 Early detection due to screening, more effective adjuvant therapies, and lower rates of 
hormone replacement therapies have contributed to the declining mortality rates in the recent 
years.171 Breast cancer is generally classified into three categories: hormone receptor (ER) 
positive, HER2 positive and triple negative breast cancer (TNBC).171 Current treatments for 
breast cancer include: Surgery (breast-conserving or total mastectomy), radiation therapy, 
chemotherapy, hormone therapy, and targeted therapy. 
Hormone receptor positive carcinomas account for nearly 70% of all breast cancers.172 
Adjuvant hormonal therapy with tamoxifen has been the standard therapy for postmenopausal 
women with ER positive breast cancer.173 Recently, nonsteroidal aromatase inhibitors, such as 
letrozole and anastrozole have been shown to have superior effects over tamoxifen in reducing 
circulating estrogen levels. These compounds are currently approved by FDA for the fist- and 
second-line treatment of ER positive metastatic breast cancer.173  
HER2 positive subtype accounts for 20-30% of all breast cancers. HER2 positive breast 
cancers are more aggressive, more likely to metastasize, and show increased resistance to 
hormonal therapy.174 Adjuvant therapies that contained EGFR inhibitors, such as trastuzumab 
and lapatinib have significantly improved the clinical outcomes in HER2 positive patients.174,46  
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TNBCs constitute 15-20% of all the breast carcinomas, and are clinically defined as 
tumors that lack immunohistochemical expression of estrogen receptors (ER), progesterone 
receptors (PR) and HER2 overexpression.175,176 This infamous subtype of breast cancer is known 
for its poor prognosis, aggressiveness, high rates of brain metastases and greater incidence of 
early recurrence with median survival rate of approximately 1 year.175 Since TNBCs are 
generally resistant to chemotherapy with currently no alternative treatments available to those 
affected, it seems imperative to identify new molecular targets that these cells rely upon for 
proliferation, differentiation and growth.171,176    
Ruxolitinib  
Manufactured by Novartis, ruxolitinib (INCB018424, Jakafi) is a selective inhibitor of 
JAK1 and JAK2 with IC50 values of 3.3 and 2.8 nM, respectively. It was approved by the FDA in 
November 2011 for the treatment of intermediate or high-risk myelofibrosis, and phase I/II 
clinical trials have manifested its capability in the reduction of splenomegaly and alleviating the 
disease-associated symptoms.177-179 Orally administered, ruxolitinib is absorbed rapidly and 
reaches Cmax within 2 hours before undergoing metabolism by the hepatic CYP3A4 system with 
its mean half-life within the range of 3-4 hours.177,179,180 The mean Cmax value for a single dose of 
25mg of the drug was measured to be approximately 1093 nM.177,181 Throughout the clinical 
studies, ruxolitinib was well tolerated by the patients who received a safe dose of 15 mg bid, and 
the toxic effects have been limited to ecchymosis, anemia, dizziness and headache.177,179 
Ruxolitinib binds in the ATP binding pocket of its targets, inhibiting both wild-type JAK1 and 
JAK2 and mutant JAK2 V617F (a gain-of-function mutation commonly observed in 
myelofibrosis).179 Clinical studies have also demonstrated that ruxolitinib, through inhibition of 
JAK1 and JAK2, suppressed phosphorylated-STAT3 and -STAT5 resulting in a reduction in 
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signal transduction and inflammatory cytokine levels, including IL-6, TNF α, and macrophage 
inflammatory protein 1β.178,179  
                                                               
Figure 48. Chemical structure of ruxolitinib phosphate.182  
 
Lapatinib 
 Developed by GlaxoSmithKline, lapatinib (GW-572016, Tykerb) is a selective inhibitor 
of EGFR/ERBB-1 and Her-2/ERBB-2 signaling, with IC50 values of 10.2 and 9.8 nanomolar, 
respectively.183-186  In January 2010, lapatinib was granted accelerated FDA approval to be used 
in combination with letrozole for the treatment of postmenopausal women with hormone 
receptor positive metastatic breast cancer that over-express ErbB-2 receptor (more information 
available at http://www.cancer.gov/about-cancer/treatment/drugs/fda-lapatinib). Lapatinib 
exhibits reversible, non-covalent inhibition of EGFR and ErbB-2 by binding in the ATP-binding 
cleft located on the intracellular kinase domain of these receptors.183 This leads to suppression of 
signal transduction through downstream pathways, including Ras/MAPK, and PI3K/AKT 
pathway, ultimately resulting in growth arrest or apoptosis of cancer cells.184  Lapatinib reaches 
its plasma Cmax of nearly 4 μM 3-4 hours after the oral administration, and is metabolized mostly 
by the hepatic CYP3A4 system. The elimination half-life of lapatinib is about 14 hours after 
single dose administration.185 Lapatinib caused minimal toxic effects in patients who received a 
daily dose of 1500 mg with the adverse events being limited to diarrhea, skin rash, and fatigue.186  
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Figure 49. Chemical structure of lapatinib.185 
Afatinib 
 Developed and manufactured by Boehringer Ingelheim, afatinib (BIBW2992, Gilotrif) is 
an oral inhibitor of ERBB family of tyrosine kinases.187-189 It binds EGFR, ErbB2 and ErbB4 
receptors with high selectivity with IC50 values of 0.5, 14 and 1nM, respectively.
187,188 Afatinib 
carries a Michael acceptor group, which allows for covalent binding to specific residues within 
the ATP binding pocket of its targets, resulting in irreversible inhibition of receptor 
autophosphorylation.188 It also blocks transphosphorylation of ErbB3.187 In the United States, 
afatinib is approved for the treatment of patients with metastatic NSCLC whose tumors contain 
EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.187 Afatinib is absorbed 
relatively fast, with steady state being reached within 8 days.187,188 The mean half-life of afatinib 
is 30-48 hours.188 It goes through minor hepatic metabolism, and is mainly eliminated via feces 
(85%), and urine (4%).187 Afatinib caused minimal toxicity in patients who received a 
recommended daily dose of 40 mg, with side effects being limited to rash and diarrhea.187,188                                                                
                                        
Figure 50. Chemical structure of Afatinib.188
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The drug Combination Rationale 
EGFR amplification and overexpression is commonly observed in many breast cancers, 
including 30-52% TNBC carcinomas.190,191 It has been well documented that the tumors with 
alterations in EGFR receptor are more aggressive in nature and lead to more dismal clinical 
outcome.82 Therefore, EGFR-targeted therapy in all types of breast carcinoma, including TNBC, 
emerged as a promising approach with many agents such as cetuximab, trastuzumab and 
lapatinib employed in numerous clinical trials.46,82,174 However, there is growing evidence that 
inhibition of ErbB receptors as a monotherapy is not adequate for blocking the malignancy, and 
the combination of targeted inhibitors will most likely present a more feasible approach.82  
Prior studies have suggested a prominent role for cytokine receptor signaling through 
JAK/STAT pathway in breast carcinogenesis, and prolactin, erythropoietin, and other cytokines 
such as IL-6 and IL-11 have been linked to an increase in breast cancer incidence.192-195 In 
addition, STAT3 and STAT5 activation have been shown to contribute significantly to the 
induction of mammary carcinogenesis.196,197 Between the two, STAT3 acts as a point of 
convergence for many well-known oncogenic pathways, and its role in promoting tumorigenesis 
and drug resistance has been supported by numerous studies.198,199 However, no inhibitor of 
STAT3 has been approved by FDA yet.198 Furthermore, EGFR and STAT signaling crosstalk 
through different mechanisms.200 For instance, EGFR signaling can activate STAT3 in a process 
mediated by Src family of kinases, and STAT3 has been demonstrated to upregulate ErbB2 
transcription in metastatic HER2 positive breast cancer.83,201 These findings led us to hypothesize 
that the concurrent inhibition of JAK/STAT and EGFR pathways would cause detrimental 
effects in breast cancer cells. Since there are no FDA-approved STAT inhibitors available at the 
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moment, and knowing that STAT3 and STAT5 are both heavily involved in breast cancer, we 
repurposed ruxolitinib, a JAK1/2 inhibitor, as a novel therapeutic in treatment of breast cancer. 
Hypothesis 
 Concurrent inhibition of JAK/STAT and EGFR signaling pathways induces cell death in 
breast cancer cells, and profoundly reduces mammary tumor growth.  
 
 
 
 
            
Table 2. Breast cancer cell lines used in this study. 
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Results 
Ruxolitinib and lapatinib synergize to kill breast cancer cells 
 Initial studies determined whether the ERBB1/2/4 inhibitor lapatinib (referred to as LAP 
in the figures) interacted with the JAK1/2 inhibitor ruxolitinib (referred to as RUX in the figures) 
to kill breast cancer cells. Our data indicated that lapatinib and ruxolitinib strongly interacted to 
kill a variety of breast cancer cells, including cells from all three subtypes; triple negative 
(SUM149PT, HCC38 and BT549), HER2 positive (BT474), and ER positive (MCF7) (Fig 51).  
The synergistic interaction between ruxolitinib and lapatinib was determined by colony 
formation assay. Median dose effect isobologram analysis to determine synergism of drug 
interaction was carried out according to the methods of Chou and Talalay using the CalcuSyn 
program.151 The data suggested that ruxolitinib and lapatinib interacted in a synergistic fashion to 
kill SUM149PT cells, with combination index (CI) values significantly below 1.0 (Figure 52). 
 Next, using molecular tools, we defined which ERBB family members in different cell 
types were responsible for the interaction of ERBB receptor inhibitors and ruxolitinib. 
SUM149PT cells were isolated from an inflammatory breast cancer patient whose tumor was 
defined as “triple negative” but which nevertheless in our hands expressed detectable basal levels 
of ERBB1, ERBB2, ERBB3 and ERBB4 by immuno-fluorescence of cells fixed in situ. In 
SUM149PT cells combined inhibition of ERBB1 and ERBB2 or ERBB1, ERBB2 and ERBB4 
strongly enhanced ruxolitinib toxicity (Figure 53). 
 Ruxolitinib is claimed to be a specific inhibitor of the Janus kinases JAK1 and JAK2, but 
does not block JAK3 or TYK2. Thus we next determined whether knockdown of JAK1 and 
JAK2 could account for the effects of ruxolitinib. Knockdown of both JAK1 and JAK2 enhanced 
the lethality of lapatinib (Figure 54). 
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Figure 51. Ruxolitinib and lapatinib interact to kill breast cancer cells. Indicated cells were 
treated with vehicle (DMSO), ruxolitinib-phosphate (1.0 M), lapatinib tosylate (1.0 M) or the 
drugs in combination. Cell viability was assessed 24 hours after drug exposure using a Hermes 
Wiscan instrument (n = 3, ± SEM). *P< 0.05 greater than corresponding value in VEH cells. 
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Figure 52. CI values provide proof of synergy between ruxolitinib and lapatinib. 
SUM149PT cells were plated (250-1500 cells/well) in sextuplicate, and were treated with vehicle 
(DMSO), ruxolitinib (0.25-1.50 µM), lapatinib (0.25-1.50 µM), or with both drugs combined. 24 
hours after drug exposure, the medium was changed and cells were cultured in fresh medium for 
10-14 days. Cells were then fixed and stained with crystal violet, and colonies were counted. 
Colony formation data were entered into the CalcuSyn program and CI values were determined. 
Based on this method, a combination index value of < 1.00 indicates synergistic effect, a value of 
1.00 indicates additivity, and a value of greater > 1.00 equates antagonism of action between the 
drugs (n = 2; 12 individual wells per data point ± SEM). 
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Figure 53. Inhibition of ERBB receptors enhances ruxolitinib toxicity. SUM149PT cells 
were transfected with a scrambled siRNA (siSCR) or with siRNA molecules to knock down the 
expression of ERBB1, ERBB2 and ERBB4 in combinations, as indicated in the figure. 24 hours 
after transfection cells were treated with vehicle control or ruxolitinib (0.5, 1, or 2 M), as 
indicated. Cell viability was assessed 24 hours after drug exposure using a Hermes Wiscan 
instrument (n = 3, ± SEM). *P< 0.05 greater than corresponding value in siSCR cells. 
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Figure 54. Inhibition of JAK1 and JAK2 enhances lapatinib toxicity. SUM149PT cells were 
transfected with a scrambled siRNA (siSCR) or with siRNA molecules to knock down the 
expression of JAK1 and JAK2 in combination. 24 hours after transfection cells were treated with 
vehicle control or lapatinib (1 or 2 M), as indicated. Cell viability was assessed 24 hours after 
drug exposure using a Hermes Wiscan instrument (n = 3, ± SEM). *P< 0.05 greater than 
corresponding value in siSCR cells. 
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Ruxolitinib and lapatinib combination alter multiple survival signaling pathways 
 Ruxolitinib and lapatinib modulate the functions and activities of many intracellular 
signal transduction pathways, and we next explored the impact our ruxolitinib based drug 
combination had on cell signaling processes. In SUM149PT cells lapatinib and ruxolitinib 
inhibited the phosphorylation of EGFR, STAT3 and STAT5, as would be expected based on 
their declared kinase specificities (Figures 55). Drug combination treatment of SUM149PT cells 
reduced activity within the ERK1/2, p65 NFB and AKT signaling pathways. The reduced 
activities within those well described “protective” signal transduction pathways correlated with 
reduced MCL-1 and Bcl-xL expression within 6 hours. The drug combination also increased the 
phosphorylation of JNK. To further examine changes in cell signaling after drug exposure we 
then made use of multiplex antibody array assays in a Bio-Rad MAGPIX machine (Figure 56A 
and B). The combination of ruxolitinib and lapatinib decreased the expression of multiple 
protective and pro-inflammatory cytokines, including CXCL1, IL-1β and IL-8, and as observed 
using immunoblotting, inactivated ERK1/2, AKT and NFB signaling. In addition, the drug 
combination also reduced the phosphorylation of BAD, CREB, p70S6K and PDGFRα. 
 Based on the survival pathways that were inhibited by the drug combination, we further 
assessed if the inhibition of these pathways were involved in the induction of cell death. In 
SUM149PT triple negative breast cancer cells, expression of an activated form of STAT3, an 
activated form of AKT, an activated form of MEK1/2, an activated form of mTOR, or pre-
treating cells with JNK inhibitory peptide suppressed the lethality of the drug combination 
(Figure 57).  
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Figure 55. The LAP+RUX combination alters major signal transduction pathways. 
SUM149PT cells were treated with vehicle (DMSO), ruxolitinib (1.0 µM), lapatinib (1.0 µM), or 
the drug combination for 6 and 12 hours. Cells were lysed and expression of indicated proteins 
was determined by immunoblotting. 
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Figure 56. Multiplex analysis of SUM149PT cells treated with ruxolitinib, lapatinib or the 
drug combination. (A) and (B) SUM149 cells were treated with vehicle (DMSO), ruxolitinib 
(1.0 M), lapatinib (1.0 M) or the drugs in combination for 4h, for 8h and for 12h. At each time 
point cells were lysed and clarified by centrifugation. Clarified tumor cell lysates were then 
subjected to multiplex assays as described in the methods to detect the plasma levels of the 
indicated cytokines and phosphorylation status of signal transduction proteins using a BIO-RAD 
MAGPIX multiplex instrument (n = 3 ± SEM). 
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Figure 57. Inhibition of JNK1/2 or activation of STAT3, AKT, mTOR, and 
MEK1suppresses the LAP+RUX combination lethality. SUM149PT cells were transfected 
with plasmids to express either empty vector (CMV), activated STAT3 (caSTAT3), activated 
MEK1 (caMEK1), activated AKT (caAKT), or activated mTOR (ca mTOR). 24 hours after 
transfection, cells were treated with vehicle (DMSO) or ruxolitinib (1.0 µM) + lapatinib (1.0 
µM) combination. Cell viability was assessed 24 hours after drug exposure using a Hermes 
Wiscan instrument (n = 3, ± SEM). *P< 0.05 lower than corresponding value in CMV cells. For 
JNK1/2 inhibition, plated cells were treated with the JNK inhibitory peptide (JNK-IP) for 30 
minutes before the drugs were added accordingly. The viability was determined in a similar way 
using a Hermes Wiscan instrument.  
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Ruxolitinib and lapatinib combination induces cell death via apoptosis, autophagy and 
necroptosis  
 We next investigated the molecular mechanisms by which the combination of ruxolitinib 
and lapatinib was killing tumor cells. Initial studies using pharmacologic tools demonstrated that 
killing induced by the drug combination was suppressed by inhibition of RIP-1 (necroptosis; 
necrostatin-1), PI3K (autophagy; 3-methyl adenine (3-MA)), and caspases (apoptosis; Z-VAD) 
(Figure 58). Thus, we next determined whether the activation of intrinsic and extrinsic apoptotic 
pathways was triggered in the drug combination-treated cells. Inhibition of caspase 8 (death 
receptor signaling) by overexpression of c-FLIP-s did not significantly reduce the lethality of the 
drug combination treatment. Inhibition of caspase signaling downstream of mitochondria by 
expression of dominant negative caspase 9 partially suppressed the drug combination toxicity. 
Overexpression of Bcl-xL or knockdown of either BAX or BAK strongly reduced drug 
combination killing (Figures 59 and 60). Although knock down of PUMA or NOXA was 
protective, the effect of either knockdown on maintaining cell viability was less than that of 
inhibiting both BAX and BAK function together. Additionally, knockdown of BID and AIF 
reduced the drug combination-mediated lethality (Figure 61). 
 AIF is a mitochondrial protein that is released into the cytoplasm upon a lethal stimulus, 
and it then re-locates to the nucleus where it acts to promote a non-caspase dependent 
fragmentation of the DNA.202 In unstimulated SUM149PT cells AIF co-localized with the 
mitochondrial protein AAA+ ATPase protein ATAD3A but not with the nuclear protein eIF3A. 
Six hours after treatment with the combination of ruxolitinib and lapatinib, the co-localization of 
AIF with ATAD3A appeared to remain similar; however the association of AIF with eIF3A in 
the nucleus had increased (Figure 62).  
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Figure 58. The LAP+RUX combination induces cell death via apoptosis, autophagy and 
necroptosis. Plated SUM149PT cells were pre-treated with necrostatin-1, 3-MA, or Z-VAD for 
45 minutes and were then exposed to the drugs individually or in combination as indicated. Cell 
viability was assessed 24 hours after drug exposure using a Hermes Wiscan instrument (n = 3, ± 
SEM). *P< 0.05 lower than corresponding value in VEH cells.   
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Figure 59. The LAP+RUX combination activates intrinsic apoptotic pathway. SUM149PT 
cells were infected with recombinant adenoviruses to express empty vector (CMV), dominant 
negative caspase 9 (DN casp 9), Bcl-xL, or c-FLIP-s. 24 hours after infection cells were treated 
with vehicle (DMSO), or the combination of ruxolitinib (1.0 µM) and lapatinib (1.0 µM). Cell 
viability was assessed 24 hours after drug exposure using a Hermes Wiscan instrument (n = 3, ± 
SEM). *P< 0.05 lower than corresponding value in CMV cells.    
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Figure 60. Knockdown of BAX and BAK significantly suppresses the LAP+RUX 
combination lethality. SUM149PT cells were transfected with a control scrambled siRNA 
(siSCR) or two different siRNAs to knockdown expression of BAX and BAK. 24 hours after 
transfection cells were treated with vehicle (DMSO), or the combination of ruxolitinib (1.0 µM) 
and lapatinib (1.0 µM). Cell viability was assessed 24 hours after drug exposure using a Hermes 
Wiscan instrument (n = 3, ± SEM). *P< 0.05 lower than corresponding value in siSCR cells. 
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Figure 61. Knockdown of PUMA, NOXA, BID and AIF reduces the LAP+RUX 
combination lethality. SUM149PT cells were transfected with a control scrambled siRNA 
(siSCR) or different siRNAs to knockdown expression of NOXA, PUMA, BID and AIF. 24 
hours after transfection cells were treated with vehicle (DMSO), or the combination of 
ruxolitinib (1.0 µM) and lapatinib (1.0 µM). Cell viability was assessed 24 hours after drug 
exposure using a Hermes Wiscan instrument (n = 3, ± SEM). *P< 0.05 lower than corresponding 
value in siSCR cells. 
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Figure 62. AIF translocates to the nucleus 6 hours after drug exposure. SUM149PT cells 
were treated with vehicle (DMSO), or the combination of ruxolitinib (1.0 µM) and lapatinib (1.0 
µM) as indicated for 6 hours after which cells were fixed in place and permeabilized using 0.5% 
Triton X100. Immuno-fluorescence was performed at 60X magnification to detect the co-
localization levels of the indicated proteins, and for the total expression level of AIF. 
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 Based on the preliminary data from 3-MA-treated cells, and also knowing that 
overexpression of mTOR was strongly protective, we next investigated the induction of 
autophagy in SUM149PT cells in response to the drug combination. . Treatment of cells with the 
combination of ruxolitinib and lapatinib increased the numbers of autophagosomes in cells in a 
greater than additive fashion and in a time-dependent fashion (Figure 63).  In agreement with our 
preliminary data using 3-MA, knock down of Beclin1 or of ATG5 suppressed, but did not 
completely abolish, tumor cell killing by the drug combination (Figure 64).   
 Of note, the treatment of cells with the drug combination caused LC3-GFP intense 
staining vesicles to co-localize with the mitochondria, an indicator of mitophagy (Figure 65). 
Treatment of cells with the combination of ruxolitinib and lapatinib also caused LC3-GFP 
staining vesicles to co-localize with acidic lysosomes (Figure 66).  
 We next determined whether the induction of autophagosome formation was an essential 
process for activation of BAX and BAK above the level of mitochondrial dysfunction or whether 
it was a consequence downstream of an early form of mitochondrial dysfunction. Treatment of 
SUM149 cells with the combination of ruxolitinib and lapatinib activated the toxic BH3 domain 
proteins BAX and BAK (Figure 67). Activation of BAX was almost abolished by knockdown of 
Beclin1 or of BID expression, whereas activation of BAK was only modestly impacted by BID 
knockdown (Figure 67). 
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Figure 63. The LAP+RUX combination increases autophagosome formation. SUM149 cells 
were transfected with a plasmid to express LC3-GFP. Twenty four hours after transfection cells 
were treated with vehicle (DMSO), lapatinib (1.0 M), ruxolitinib (1.0 M), or in combination 
as indicated for 6 or 12 hours. At each time point cells were visualized using a fluorescent 
microscope at X40 magnification and the mean number of intense punctate GFP positive vesicles 
per cell determined in > 40 cells from random fields ± SEM (*p < 0.05 greater than lapatinib 
alone or ruxolitinib alone treatments). 
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Figure 64. Knockdown of Beclin1 and ATG5 reduces the lethality of the LAP+RUX 
combination. SUM149PT cells were transfected with a control scrambled siRNA (siSCR) or 
two different siRNAs to knockdown expression of Beclin1 and ATG5. 24 hours after 
transfection cells were treated with vehicle (DMSO), or the combination of ruxolitinib (1.0 µM) 
and lapatinib (1.0 µM). Cell viability was assessed 24 hours after drug exposure using a Hermes 
Wiscan instrument (n = 3, ± SEM). *P< 0.05 lower than corresponding value in siSCR cells. 
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Figure 65. The LAP+RUX combination induces mitophagy. SUM149PT cells were 
transfected with a plasmid to express LC3-GFP. 24 hours after transfection cells were treated 
with vehicle (DMSO), lapatinib (1 M), ruxolitinib (1 M) or in combination as indicated for 6 
hours. Cells were then treated with MitoTracker Red CMXRos (25 nM) for 30 min. Cells were 
visualized using a fluorescent microscope at 40X magnification in the red and green fluorescent 
channels. The red and green images were merged in Adobe Photoshop CS6; areas of yellow 
staining indicate the co-localization of GFP and MitoTracker Red staining. 
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Figure 66. The LAP+RUX combination induces co-localization of autophagosomes to 
lysosomes. SUM149PT cells were transfected with a plasmid to express LC3-GFP. 24 hours 
after transfection cells were treated with vehicle (DMSO), lapatinib (1 M), ruxolitinib (1 M) 
or in combination as indicated for 6 hours. Cells were then treated with LysoTracker Red DND-
99 (25 nM) for 30 min. Cells were visualized using a fluorescent microscope at 40X 
magnification in the red and green fluorescent channels. The red and green images were merged 
in Adobe Photoshop CS6; areas of yellow staining indicate the co-localization of GFP and 
LysoTracker Red staining. 
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Figure 67. Knockdown of Beclin1 abolishes activation of BAX and BAK. SUM149PT cells 
were transfected with a scrambled nonsense siRNA molecule (siSCR), or siRNA molecules to 
knockdown the expression of BID or of Beclin1. 24 hours after transfection cells were treated for 
6 hours with vehicle (DMSO) or with ruxolitinib (1 M) and lapatinib (1 M) combination for 6 
hours. Cells were isolated and broken down using CHAPS based lysis buffer with vigorous 
trituration, followed by lysate clarification via centrifugation (5 min x 14,000 g). Equal protein 
mass portions of lysates were immunoprecipitated using antibodies that recognize epitopes in 
BAX and in BAK only open to detection when these toxic BH3 domain proteins are active. The 
total expression of BAX and of BAK under each condition was assessed by immunoblotting.          
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Discussion 
This study was conducted to determine whether the concurrent inhibition of JAK/STAT 
and ERBB signaling could synergize to kill breast cancer cells. As stated before, EGFR 
amplification and overexpression is commonly observed in many breast cancers, including 30-
52% TNBC carcinomas.190,191 In addition, prior studies have suggested a prominent role for 
cytokine receptor signaling through JAK/STAT pathway in breast carcinogenesis, and prolactin, 
erythropoietin, and other cytokines such as IL-6 and IL-11 have been linked to an increase in 
breast cancer incidence.192-195 Furthermore, EGFR and JAK/STAT signaling pathways have been 
shown to crosstalk through different mechanisms.200 These reports led us to hypothesize that 
concurrent inhibition of these two pathways could be a potent novel therapeutic approach in 
treatment of breast cancer. Since there are no FDA-approved STAT inhibitors available at the 
moment, and knowing that STAT3 and STAT5 are both heavily involved in breast 
carcinogenesis, we repurposed ruxolitinib, a JAK1/2 inhibitor, as a novel therapeutic in treatment 
of breast cancer. 
 Our initial data indicated that lapatinib and ruxolitinib strongly interacted to kill a variety 
of breast cancer cells, including cells from all three subtypes; triple negative (SUM149PT, 
HCC38 and BT549), HER2 positive (BT474), and ER positive (MCF7). Colony formation 
assays and CI values were very well indicative of the synergistic interaction between the two 
drugs. Moreover, using molecular tools, we demonstrated that the inhibition of ERBB receptors 
and JAK1 and JAK2 is the major reason behind the strong interaction between these two kinase 
inhibitors. Knockdown of ERBB1/2/4 in SUM149PT cells recapitulated the toxic interaction 
with ruxolitinib. Similarly, combined knockdown of JAK1 and JAK2 could recapitulate the toxic 
effects of ruxolitinib when combined with ERBB1/2/4 inhibitors.  
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 Lapatinib and ruxolitinib, as expected based on their declared kinase specificities, 
inhibited the phosphorylation of EGFR, STAT3 and STAT5. Additionally, the combination of 
the two drugs reduced activities within those well described survival signal transduction 
pathways, such as ERK1/2, p65 NFB and AKT, which correlated with reduced MCL-1 and 
Bcl-xL expression within 6 hours. Further unbiased multiplex analyses indicated that the 
combination of ruxolitinib and lapatinib decreased the expression of multiple protective and pro-
inflammatory cytokines, including CXCL1, IL-1β and IL-8, as well as the phosphorylation of 
BAD, CREB, p70S6K and PDGFRα. Decreased phosphorylation of CREB, BAD and p70S6K 
correlated with the decreased P-ERK1/2 and P-AKT as demonstrated by both immunoblotting 
and multiplex assay. However, a decrease in PDGFRα phosphorylation, which was also observed 
in cells treated with ruxolitinib alone, was somewhat unexpected, but could provide further 
evidence as why these two kinase inhibitors interacted in such synergistic fashion. In agreement 
with our data form multiplex assays and immunoblotting, overexpression of MEK1, STAT3, 
AKT and Bcl-xL significantly protected the cells, further providing proof for involvement of 
these inhibited signal transduction proteins in the induction of cell death. Studies to define the 
downstream effectors of AKT, STAT3 and ERK1/2 signaling that regulate the threshold for cell 
killing in the presence of ruxolitinib and lapatinib are outside the scope of the present 
manuscript. 
 As p70S6K phosphorylation, an mTOR substrate, was reduced, and the expression of an 
activated form of mTOR as well as pre-treating the cells with 3-MA strongly protected the cells, 
we next investigated the role of autophagy in cell death. In accordance with 3-MA data, the 
inhibition of Beclin1 and ATG5 significantly protected the cells. The drug combination 
increased the number of the LC3-GFP vesicles in a greater than additive fashion, and the LC3-
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GFP vesicles were shown to co-localize to the acidic lysosomes in the combination-treated 
group. We also discovered that the drug combination induced mitophagy, as the LC3-GFP 
stained autophagosomes were shown to co-localize to the mitochondria.  
Since pan-caspase inhibitor Z-VAD strongly suppressed the drug combination-mediated 
lethality, we next determined if the extrinsic and intrinsic apoptotic pathways were activated by 
the combination of ruxolitinib and lapatinib. The expression of dominant negative caspase 9 
modestly protected the cells whereas the overexpression of c-FLIP-s did not protect the cells at 
all. This was specifically interesting since the knockdown of BID, a substrate of caspase 8, was 
strongly protective. The toxic BH3 domain protein BID is activated by proteolytic cleavage; a 
cleavage most commonly thought to be catalyzed by caspases 8 and 10 downstream of death 
receptors but also less commonly by cathepsin and calpain proteases released due to lysosomal 
dysfunction/autophagy flux.203 More studies will be required to determine if the cleavage of BID 
occurs through cathepsin and calpain proteases. We also demonstrated that the mitochondrial 
permeabilization occurred through activation of BAX and BAK, which subsequently led to the 
release of AIF and its translocation to the nucleus. 
Furthermore, our data indicated that activation of BAX and BAK was dependent on 
activation of autophagy and that the induction of autophagosome formation was an essential 
process for activation of BAX and BAK above the level of mitochondrial dysfunction. 
As ruxolitinib and lapatinib interacted in a synergistic fashion to kill a variety of breast 
cancer types, we are planning to further expand our studies in the future by evaluating the 
efficacy of the drug combination in vivo. We are also concurrently evaluating a potential 
replacement of lapatinib with the more potent new generation ERBB inhibitor afatinib, which 
irreversibly inactivates ERBB1/2/4 and also blocks transphosphorylation of ErbB3. 
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Figure 68. Proposed mechanism of cell death induced by the combination of RUX and 
LAP. The combination of ruxolitinib and lapatinib reduced the phosphorylation of AKT, 
ERK1/2 and p65 NFB, which correlated with reduced MCL-1 and Bcl-xL expression. It also 
induced cell death through activation of JNK. The drug combination induced cytotoxic 
mitophagy, which acted upstream of the mitochondrial dysfunction, as Beclin1 mediated 
activation of BAX and BAK. Cleavage of BID also occurred in response to the treatment with 
the drug combination. As caspase 8 inhibition was not protective, we suspect that the cleavage of 
BID could have been mediated by cathepsins and calpains. In addition, mitochondrial 
dysfunction led to the release of AIF and its translocation to the nucleus. (Guide:       represents 
explored pathways,        represents unexplored but feasible pathways) 
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Conclusion 
 In conclusion, the combination of ruxolitinib and lapatinib interacted to kill a variety of 
different breast cancer cells, including triple negative, HER2 positive and ER positive, in a 
synergistic fashion. Using pharmacologic and molecular tools, we demonstrated that the killing 
induced by the drug combination was mediated via necroptosis, apoptosis, and autophagy. We 
also demonstrated that the inhibition of ERBB receptors and JAK1 and JAK2 is the major reason 
behind the strong interaction between these two kinase inhibitors. Moreover, our data 
demonstrated that the induction of autophagosome formation and mitophagy acted upstream of 
the mitochondrial dysfunction, as knockdown of Beclin1 abolished BAX and BAK activation. In 
addition, we showed that whereas the inhibition of caspase 8 was not protective, the knockdown 
of BID significantly protected the cells. Therefore, this proteolytic cleavage of BID could be 
mediated by the cathepsin and calpain proteases although more studies will be required to fully 
elucidate the mechanism of BID activation. Our data also argued that the translocation of AIF 
from mitochondria to the nucleus played a significant role in inducing cell death.  
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CHAPTER 5: Concluding Remarks 
  
 The ultimate goal of the studies in this manuscript was to propose novel potent 
combinatorial targeted therapies for the treatment of cancers of liver, colon and breast using 
FDA-approved drugs. The aforementioned cancers are amongst the top five most prevalent and 
most fatal worldwide. Currently, surgical resection, radiotherapy and adjuvant chemotherapy, in 
some cases combined with certain approved targeted agents, constitute the front line therapies for 
HCC and CRC. Likewise, breast cancer, based on its characteristics, is usually treated with the 
combination of surgery, radiotherapy, chemotherapy, hormonal and targeted therapy.  
 The recent advancements in cancer genomics and identification of commonly mutated 
oncogenes coupled with poor chemotherapy response rates have shifted cancer therapy towards a 
more targeted approach based on better understanding of cancer biology.11 Evidently, unlike 
chemotherapy, the major benefit of this type of tailored therapy is that it only interferes with 
distinct molecular targets that the cancer cells physiologically depend on, thereby providing high 
specificity, a broader therapeutic index, and less nonspecific toxicities.12 However, a major 
setback to single-agent targeted therapy is the activation of parallel survival pathways. This 
oncogenic bypass mechanism results in the cell activating an alternative survival pathway in the 
event of blockade of a specific pathway; thus, leading to drug resistance.22,23 Recent clinical 
trials have provided convincing evidence that the use of targeted therapeutics in combination 
provides a more rational strategy to increase the efficacy of the treatments.11  
 Mutations in ras gene have been frequently observed in liver and colorectal cancers, 
which led to approval of sorafenib and regorafenib for the treatment of HCC and CRC, 
respectively. However, both drugs only produced modest effects with low response rates in the 
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clinic.128,204 Therefore, our major aim in this study was to potentiate the effect of sorafenib 
(SOR) and regorafenib (REGO) in these cancers by identifying/blocking another molecular 
target that hepatoma and colon cancer cells rely upon to survive. Recent studies have reported 
the elevated levels of PDE5 expression in many cancers including colon adenocarcinoma and 
commonly used colon cancer cell lines HT29 and HCT116 cells.147,205 Activation of cGMP/PKG 
pathway reduces cellular growth and induces apoptosis through induction of β-catenin, which 
subsequently inhibits the function of multiple downstream survival proteins such as cyclin D1 
and survivin.205 Thus, elevated levels of PDE5, the enzyme that hydrolyzes cGMP, has been 
suggested to be involved in cancer progression.205 We alongside our colleagues at VCU had 
previously reported the enhancing effect of PDE5 inhibitors in chemotherapy cell killing.145-147 
In these studies PDE5 inhibitors, in a NOS-dependent fashion, were shown to enhance 
chemotherapy effect through activation of CD95 receptors, the generation of ROS, and 
mitochondrial dysfunction.145-147 As mentioned earlier in chapter 1, the cofactor BH4 plays a 
critical role in NOS activity. Small ratio of BH4 relative to its oxidized form, BH2, causes NOS 
uncoupling, leading to production of ROS and RNS rather than NO.87,89 New studies have 
indicated that BH4:BH2 ratio is significantly lower in tumor cells than in normal tissue.206 Thus, 
whereas sildenafil (SIL) is often associated with reduced oxidative stress in non-transformed 
cells, it promotes oxidative stress in tumor cells.156 In agreement with these reports, we observed 
a significant increase in ROS and RNS levels as early as 2 hours after drug exposure. Our results 
suggested that the NOS activity and the ROS generation played a significant role in triggering a 
cytotoxic form of autophagy, and mediating cell death through activation of CD95 death receptor 
pathway. The crucial role of CD95 death receptor activation in [SOR/REGO+SIL]-mediated cell 
death was very well elucidated via expression of wild type CD95 in CD95 null- HUH7 cells. 
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Additionally, prior studies had indicated that the pro-apoptotic effect of cGMP/PKG pathway 
was also mediated through JNK.205 Accordingly, our data showed an increase in phospho-
JNK1/2 level in cells treated with REGO+SIL combination, and the pre-treatment of cells with 
JNK inhibitory peptide almost abolished the drug combination toxicity. Moreover, our in vivo 
tumor analysis revealed a significant increase in phospho-c-Jun level, which further approves the 
pro-apoptotic role of JNK. Furthermore, the drug combination inhibited the AKT/mTOR 
pathway, which was shown to play a major role in induction of cell death as the expression of an 
activated form of mTOR significantly reduced the [SOR/REGO+SIL]-mediated lethality. 
Reduction in phospho-AKT and phospho-mTOR levels could be the direct outcome of PDGFR 
inhibition, which our laboratory has repeatedly shown to be a major target for SOR and REGO.  
 SOR and REGO also induced ER stress. These drugs rapidly down-regulated GRP78, 
which resulted in a prolonged intense ER stress response leading to mitochondrial dysfunction.  
In addition to GRP78, recent studies from our laboratory indicated that these multi-kinase 
inhibitors interrupted the function of multiple other chaperones including HSP70, HSP90 and 
HSP27. Inhibition of multiple chaperones by SOR and REGO in cancer cells, which generally 
express more proteins than non-transformed cells and are heavily dependent on protein folding 
machinery, adds up another layer to the broad anti-tumor effects of these drugs.207  
 Collectively, the lethal effect of SOR/REGO+SIL combination in vitro is primarily 
mediated by the inhibition of multiple chaperones (induction of severe ER stress), the blockade 
of PDGFR signaling (decreased AKT/mTOR signaling), The NOS-dependent generation of 
ROS/RNS, pro-apoptotic function of JNK, and activation of CD95 death receptor signaling 
pathway. This explains why this drug combination responded well in multiple genetically diverse 
tumor cell types regardless of Ras mutation status.  
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 The toxic effect of this drug combination translated well into our mouse models carrying 
pre-formed tumors as the combination of SOR+SIL and REGO+SIL profoundly reduced the 
growth of HUH7 and HT29 tumors in vivo, respectively. In addition, the ex vivo colony 
formation data revealed  a significant reduction in plating efficiency of the cells treated with the 
combination of REGO+SIL as compared to REGO alone, which further approves the enhancing 
effect of PDE5 inhibition on REGO toxicity. Plus, the REGO+SIL combination-treated mice had 
significantly lower levels of VEGF and angiopoietin in their blood serum compared with the 
control group. The blockade of angiogenesis could be another way by which the drug 
combination exerted its anti-tumor effect in the mouse models. Collectively, the drug 
combination anti-tumor activity in vivo is likely an amalgamation of a direct anti-tumor cell 
killing effect by the drug combination (as previously discussed), antiangiogenic capability of 
SOR and REGO, inhibition of ABCB1/ABCG2 efflux pumps, and increased tumor vasculature 
permeability caused by the actions of sildenafil on endothelial cells.   
 In order to further tailor this drug combination, we investigated the potential addition of a 
third drug by searching for biomarkers for activated survival pathways. Prior studies from our 
group had shown that SOR could increase the levels of ceramides in hepatoma cells.152 In this 
study, REGO was noticed to have a similar effect on ceramides. REGO also increased the level 
of S1P, a sphingolipid metabolite that regulates growth, survival, migration and angiogenesis.127 
Initial in vitro studies indicated that the multiple sclerosis drug FTY720, an HDAC inhibitor and 
S1P antagonist, enhanced the toxicity of REGO and REGO+SIL combination. However, to our 
surprise, HT29 tumors in mice treated with FTY720 re-grew at a much faster rate after cessation 
of drug treatment than either REGO alone or treatment with REGO+SIL, an effect seemingly to 
be mediated by an increase in angiogenesis and tumor vascularization. Undoubtedly, FTY720 
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possesses distinct anti-tumor activity as FTY720 treatment has been previously shown to block 
colitis-associated cancer progression.149,150 However, our in vivo data demands further 
investigation into its mechanism of action as FTY720 treatment led to a significant increase in 
angiogenic/invasion regulatory cytokines.   
 In addition to S1P up-regulation, we also noticed a significant increase in phospho-AKT 
as well as stable high EGFR phosphorylation in response to the drug combination in both HUH7 
and HT29 tumors collected 7 days after the start of treatment. Inhibition of either AKT or EGFR 
enhanced the lethality of REGO+SIL combination in vitro. Thus, activation of AKT and EGFR 
seemed to be amongst the major compensatory survival pathways counteracting the toxicity of 
SOR/REGO+SIL. It certainly requires further in vivo experiments to fully validate the effects of 
AKT and EGFR inhibition on SOR/REGO+SIL combination toxicity.  
 Our in vitro and animal studies are now an open clinical trial (NCT02466802) where 
patients with all solid tumors are receiving increasing doses of REGO+SIL once daily. We’re 
hoping to be able to receive tumor and blood samples from the patients in order to analyze the 
tumor cell response and changes in the regulatory cytokines.  
 The second study in this manuscript was a proposal of a potent combinatorial targeted 
therapy for the treatment of all types of breast cancer, including the chemotherapy resistant, 
highly metastatic triple negative subtype. The study was designed based on the growing evidence 
supporting the role of STAT3 and STAT5 in breast cancer, and the heavy crosstalk between 
JAK/STAT and ERBB signaling pathways.196-201 The effect of ERBB inhibitors as single agents, 
in combination with chemotherapy, hormonal therapy, or other targeted agents have been 
extensively studied in the past with some clinical trials yielding significant improvement over 
conventional therapy.52,53,82,185 However, since there are no FDA-approved STAT inhibitors 
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currently available on the market, concurrent inhibition of STAT and ERBB signaling have not 
been examined before. In order to test this hypothesis, we utilized ruxolitinib (RUX), a JAK1/2 
inhibitor, to suppress STAT3/5 activation. Thus, this study was undertaken to determine whether 
the myelofibrosis medication RUX could be re-purposed as a solid tumor cancer therapeutic, and 
synergize with ERBB inhibitor lapatinib (LAP) to kill breast cancer cells.  
 Our in vitro results indicated that RUX and LAP strongly interacted to kill a variety of 
genetically diverse breast cancer cells, including cells from all three subtypes; triple negative, 
HER2 positive, and ER positive. Colony formation assays and CI values were very well 
indicative of the synergistic interaction between the two drugs. Moreover, using molecular tools, 
we demonstrated that the inhibition of ERBB receptors and JAK1 and JAK2 is the major reason 
behind the strong interaction between these two kinase inhibitors, which further supported our 
hypothesis.  
 With regard to the mechanism of action of this drug combination, our studies strongly 
argued that the rapid inactivation of the PI3K/AKT/mTOR pathway led to a significant increase 
in autophagosome formation; autophagosomes that co-localized with mitochondria (mitophagy) 
and with lysosomes (autolysosomes). PI3K/AKT inhibition was also associated with decreased 
phosphorylation of pro-apoptotic protein BAD (S136), which allows BAD to heterodimerize 
with Bcl-xL and Bcl-2, and trigger apoptosis.208 Furthermore, we noticed that activation of the 
executioner toxic BH3 domain proteins BAX and BAK required increased Beclin1 expression 
(autophagosome formation) and also the activation/cleavage of BID. In addition, we found that 
the autophagy-BAX/BAK/BID-dependent AIF release from the mitochondria and its 
translocation to the nucleus is one key mechanism by which the RUX+LAP combination was 
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killing tumor cells. We have our in vivo studies underway to determine if the combination of 
RUX and ERBB inhibitors become a potent therapy in the mouse models. 
 Our laboratory has constantly worked to identify new drug combinations that can be 
translated into potent therapies in the clinic. Recently, in a completed phase I trial 
(NCT01450384) proposed by our laboratory combining the anti-folate pemetrexed and SOR, 20 
out of 33 patients had prolonged stable disease or tumor regression, with one complete response 
and multiple partial responses.209 Further pre-clinical studies from our laboratory indicated that 
ERBB signaling functioned as a major compensatory survival pathway activated in response to 
SOR and pemetrexed, and that the addition of the pan ERBB inhibitor afatinib significantly 
enhanced the lethality of this drug combination.209 We hope that the addition of afatinib to the 
combination of pemetrexed and SOR would be explored in a new phase I trial as it would 
provide us with invaluable information on the feasibility of tailoring targeted therapy.  
 Having had success in the clinical trials in the past, our studies presented in this 
manuscript strongly argue that the combination of REGO+SIL and RUX+LAP can possess 
significant therapeutic value in the clinic. 
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